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Abstract
Rescue of inherited retinal degeneration associated with Aipl1 defects
Cristy Ann Ku
Since groundbreaking clinical trials treating Leber congenital amaurosis (LCA) patients
with retinal pigmented epithelium-specific 65 kDa protein (Rpe65) defects, which were the most
successful gene therapy studies to date, much effort has been put into finding other candidate
genes associated with inherited retinal degeneration to treat. Animal models with Rpe65 defects
demonstrate an unusual circumstance that greatly favors treatment, where dramatic vision loss is
disproportionately greater than the ensuing slow photoreceptor degeneration. This pattern is also
believed to occur in Rpe65-LCA patients, and stems from the primary defect in retinal pigmented
epithelial (RPE) cells that subsequently perturbs photoreceptors. However, a majority of
inherited retinal degenerations are associated with photoreceptor gene defects, and do not show
this advantageous disparity between visual dysfunction and photoreceptor loss. To combat this,
efforts have concentrated on improving photoreceptor transduction efficiency with viral vectors,
and delivering gene replacement to slower progressing retinal dystrophies.
Aryl hydrocarbon receptor interacting protein-like1 (Aipl1) is mainly associated with the
severe retinal degeneration, LCA. However, reports of Aipl1 defects in patients showing slower
progressing retinal disease, retinitis pigmentosa (RP) and cone-rod dystrophy (CORD), points to
a subset of Aipl1 patients as potential candidates for future AAV-mediated gene therapy trials.
Multiple mouse models with Aipl1 defects have been developed and contribute to the ease of
conducting pre-clinical rescue studies to examine the rescue potential of Aipl1.
To investigate the rescue potential of Aipl1 defects, we conducted AAV-mediated gene
replacement studies in Aipl1-null mice, a model for Aipl1-LCA, the most rapidly progressing of
any retinal degeneration mouse model. Our study examines the recent advancements in AAV
viral vectors, using a combined self-complementary Y733F capsid mutant AAV8 (sc-Y733FAAV8), to evaluate whether these advancements would provide functional benefits to a model of
retinal degeneration. We found that the sc-Y733F-AAV8 viral vector significantly improved
vision rescue in Aipl1-null mice as compared to conventional single-stranded AAV8, even when
treatment was administered at postnatal day 10, after initiation of photoreceptor degeneration.
From these studies, we also conclude that the Aipl1-null mouse provides a good model to test the
functional benefits of ongoing and future advancements in AAV viral vectors.
In addition to LCA, Aipl1 has been reported in patients with CORD and RP. We were
particularly interested in a mutation, P351Δ12 hAipl1 because of its association with CORD and
our ongoing interest in the role of Aipl1 in cone photoreceptors. We generated a transgenic
mouse model expressing P351Δ12 hAIPL1, which showed a cone-rod dystrophy phenotype
similar to a case of Aipl1-CORD in a patient with this mutation. The mice demonstrated early
and rapidly declining cone-mediated vision with slow progressing rod defects. Additionally, in
our studies of double transgenic mice expressing both mutant P351Δ12 hAIPL1 and WT
hAIPL1, we conclude that the P351Δ12 hAipl1 mutation does exert dominant effects that explain
the autosomal dominant inheritance pattern observed in the Aipl1 patients with this mutation.

Interestingly, despite the dominant phenotype, we were able to rescue cone dysfunction and
degeneration following AAV-mediated gene delivery of WT hAIPL1. We believe this is due to
the drastic overexpression of WT hAIPL1 that is achieved with AAV gene delivery. Further
work with this novel model of Aipl1-CORD is needed to elucidate the dominant mechanism of
the P351Δ12 hAIPL1 protein, which appear to behave differently in rods and cones, as rod
dysfunction was not rescued with AAV-mediated overexpression of WT hAIPL1. With these
successes in pre-clinical Aipl1 rescue studies, which have also been independently demonstrated
by two other groups, we conclude that Aipl1 defects show great potential for movement into
AAV-mediated gene therapy clinical trials.
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Chapter 1
Literature Review
Significance: Inherited retinal degenerations (IRD)
Hereditary retinal degeneration is a major cause of blindness affecting an estimated 1 in
3000 people (Wright et al., 2010). However, it is actually comprised of a diverse group of
blinding diseases that exhibit a spectrum of presenting symptoms and severity, with varied onset
and progression of vision loss. Leber congenital amaurosis (LCA) is the most severe of inherited
retinal degenerations (IRD), characterized by severe visual impairment within the first few
months of life and extinguished or severely reduced rod- and cone-mediated electroretinograms
(ERGs) (Schappert-Kimmijser et al., 1959; Foxman et al., 1985). Relative to LCA, retinitis
pigmentosa (RP) and cone-rod dystrophy (CORD) are less severe along the IRD spectrum,
showing later onset and slower progression to complete vision loss. RP patients present with
night blindness as the first visual impairment alongside normal visual acuity. In contrast to RP,
CORD patients initially present with decreased visual acuity, central vision loss, and
dyschromotopsia with progressive loss of peripheral, rod-mediated vision. Visual defects and
subsequent retinal degeneration stem from improper splicing, nonsense, or missense genetic
mutations translating altered, dysfunctional, or non-functional proteins whose normal function is
essential in photoreceptors or retinal pigmented epithelium (RPE).
While historically untreatable, recent breakthroughs in pre-clinical and clinical gene
replacement therapy trials have led to the potential to treat retinal dystrophies. Specifically,
adeno-associated virus (AAV)-mediated gene therapy for LCA due to retinal pigment
epithelium-specific 65 kDa protein (Rpe65) gene defects showed therapeutic effects in phase I
1

clinical trials (Bainbridge et al., 2008; Maguire et al., 2008; Cideciyan et al., 2009; Jacobson et
al., 2012) with ongoing phase II/III clinical trials (ClinicalTrials.gov, January 15, 2011). Rpe65
clinical trials are one of the most successful examples of gene therapy to date in safety and
efficacy, leading to a push for treating inherited retinal dystrophies linked to other causative
genes. An inherent challenge, however, is the multitude of associated genes implicated within
even a single inherited retinal degenerative disease, such as retinitis pigmentosa (RP) associated
with defects in over 50 genes, and the more severe Leber congenital amaurosis (LCA) associated
with defects in 16 genes (RetNet, http://www.sph.uth.tmc.edu, November 15, 2011). A majority
of these are photoreceptor genes (RetNet), making targeting of photoreceptor defects an
important next step in ocular gene therapy.
Aipl1 is one photoreceptor gene demonstrating potential for entry into clinical trials.
Aipl1 defects are associated mainly with autosomal recessive LCA, making up 7% of LCA cases
(Sohocki et al., 2000b). Additionally, Aipl1 defects are associated with RP and CORD in select
cases, pointing to a subset of Aip1l patients with a larger window of opportunity for treatment
relative to Aipl1-LCA patients. Multiple Aipl1 mouse models allow for pre-clinical testing of the
rescue potential of Aipl1 associated IRDs. Two independent Aipl1-null mouse models phenocopy
LCA, and demonstrate the most rapid photoreceptor degeneration in any mouse model of retinal
degeneration. Aipl1-null mice not only provide a uniquely suited model for testing the efficiency
of viral vectors, but also proof-of-concept that less severe retinal degenerations may successfully
be treated if the most severe of retinal degenerations is rescued. Aipl1 hypomorph mice with a
75-80% reduction in protein levels, and our novel transgenic mouse expressing patient mutation
P351Δ12 hAipl1 offer models of Aipl1-RP and -CORD, which may better predict the rescue
capacity of Aipl1 associated with less severe non-LCA IRDs.
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Retinal and retinal pigmented epithelium (RPE) defects in IRD
The neural retina is a laminated structure with three cellular layers, the outer nuclear
layer (ONL), the inner nuclear layer (INL), and the retinal ganglion cell (RGC) layer (Fig. 1A).
Rod and cone photoreceptors, which make up the ONL of the neural retina, have three distinct
cellular compartments (Fig. 1A). Photoreceptor outer segments (OS) are membranous discs that
house essential phototransduction proteins. OS are shed and regenerated daily to negate the toxic
effects of accumulated photo-oxidative products (Kevany and Palczewski 2010). Inner segments
(IS) house the cellular machinery for synthesis of proteins, including outer segment proteins
which are transported from the IS to OS via a connecting cilia (CC). The last photoreceptor
compartment, the synaptic terminal, is the site of glutamate release which signals to secondary
neurons in the INL. Visual transduction then propagates to the tertiary RGCs, the axons of which
converge and form the optic nerve, feeding information to the visual cortex.
The non-neural RPE, located between photoreceptors and the vascular choroid (Fig. 1A),
plays essential roles in the health and maintenance of photoreceptors. The RPE functions to
absorb excess light, transport nutrients and ions to the retina from the choriocapillaries, and
provide anti-oxidant and repair functions against high photo-oxidation occurring in the eye
(Kevany and Palczewski 2010). Additionally, it serves two vital functions associated with retinal
degeneration when awry: phagocytosis of shed photoreceptor outer segments; and production of
visual retinoid 11-cis retinal, necessary for generating photoactivatable opsins (Fig. 1B).
Mutations in the RPE gene, Mertk (c-mer proto-oncogene receptor tyrosine kinase), lead
to defective OS phagocytosis due to a lack of signaling for OS ingestion (Feng et al., 2002), and
is associated with retinitis pigmentosa (RetNet) and modeled by the Royal College of Surgeons
(RCS) rat. Defects in four RPE genes involved in the visual retinoid cycle are associated with
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IRD (Fig. 1B, Fig. 2) (RetNet). Lrat (lecithin retinol acyltransferase), Rdh12 (retinal
dehydrogenase 12), and Rpe65 (retinal pigmented epithelium-specific 65 kDa protein), the
genetic mutation currently treated in gene therapy clinical trials, are all associated with both RP
and LCA. Rdh5 (retinal dehydrogenase 5, or cis-RDH in Fig. 1B) is associated with CORD.
Photoreceptor gene defects are more numerous in their mechanisms of disease. Broad
mechanisms of dysfunction include, but are not all-inclusive to the following: retinal
development/retinal cell fates and structure, phototransduction cascade, photoreceptor OS
structure, and protein transport across the connecting cilium (Fig. 2). Photoreceptor genes make
up the majority of genetic defects, as compared to the four RPE genes, associated with IRD (Fig.
2). However, prior to recent advancements in AAV, transduction of the neural retina with viral
vectors was highly inefficient. In contrast, early viral-mediated ocular gene therapy demonstrated
robust RPE transduction. We first discuss the early developments in AAV-mediated gene
delivery coupled with in vivo characterization of Rpe65 defects that led to the successful
translation into Rpe65 clinical trials. Subsequently discussed are the recent advancements in viral
vectors allowing for efficient photoreceptor transduction, and the potential for treatment of the
photoreceptor gene, Aipl1.

Ocular viral gene therapy
Early ocular viral gene therapy studies, development of AAV
Attempts at ocular gene replacement therapy started in the mid 1990s, however, initial
use of adenoviral (Ad) vectors resulted in inefficient transduction of neural retinal cells and
limited duration of gene expression (Bennett et al., 1994; Jomary et al., 1994; Li, T. et al., 1994;
Li, T. and Davidson 1995; Ali et al., 1997; Wright 1997). Even in an immune privileged site of
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the eye, expression decreased by 3-4 weeks post-injection due to immune responses against viral
proteins (Li, T. et al., 1994; Reichel et al., 1998). Re-administration of Ad accelerated loss of
expression, whereas expression was prolonged in immunodeficient nude mice, further
confirming that immunogenicity hinders effective use of Ad (Reichel et al., 1998). In contrast,
early studies using recombinant adeno-associated viral (rAAV) vectors showed distinct
advantages in greater safety, photoreceptor transduction and expression duration (Ali et al.,
1996; Ali et al., 1997; Flannery et al., 1997; Jomary et al., 1997; Wright 1997).
Adeno-associated virus (AAV) is a linear single-stranded DNA virus belonging to the
Parvoviridae family and the Dependovirus genus. As implied by its name, AAV was originally
found as a contaminant in a preparation of simian adenovirus. There, it was characterized as
replication defective, requiring a helper virus such as adenovirus to replicate (Atchison et al.,
1965). AAV is non-pathogenic in humans and 40-80% of adults are seropositive for AAV
without associated symptoms or disease (Sprecher-Goldberger et al., 1971). AAV shows low
immunogenicity which is attributed to its lack of transduction and/or activation of antigenpresenting cells (APCs) (Jooss et al., 1998).
Cloning of the prototypic AAV2 into a bacterial plasmid was the first step of developing
AAV as a vector and gene transduction system (Samulski et al., 1982; Hermonat and Muzyczka
1984). Recombinant AAV vectors devoid of all viral genes except for two inverted repeats
(ITRs) between which the transgene of choice is cloned, further decreased immunogenicity by
eliminating generation of wildtype AAV (Samulski et al., 1989). Rather, a helper plasmid which
encodes AAV rep and cap genes necessary for AAV replication and viral capsid assembly,
respectively, are supplied in trans alongside infection with helper Ad during rAAV vector
production (Fig. 3), which are subsequently removed during purification.
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Although wildtype AAV can integrate into the human genome at chromosome 19q13.3qter (Kotin et al., 1991; Samulski et al., 1991), it requires AAV rep proteins which mediate
complex formation at a sequence-specific integration site (Weitzman et al., 1994). Recombinant
AAV vectors exist predominantly as non-integrated episomes in postmitotic cells (Muzyczka et
al., 1984; Duan et al., 1998; Schnepp et al., 2003; Penaud-Budloo et al., 2008; Schultz and
Chamberlain 2008; Clark and Penaud-Budloo 2011) likely due to an absence of rep proteins in
final rAAV vector preparations. Integration was however induced into double-stranded break
sites following administration of DNA damaging agents (Miller et al., 2004).
As mentioned, adenovirus (Ad) is immunogenic and pathogenic, posing problems in
production of AAV which required helper Ad for replication. Contaminating helper Ad in in vivo
AAV-mediated gene delivery elicited cellular immune responses (Mccoy et al., 1995; Monahan
et al., 1998). In addition to problematic in vivo humoral responses, presence of contaminating
helper Ad hindered effective production of purified high-titer recombinant AAV.

Production of high-titer purified AAV
Several important developments have contributed to the capacity to produce high-titer
purified AAV. First, greater understanding of the role of helper Ad in enhancement of
transcription and translation of AAV rep and cap genes and second-strand synthesis during AAV
replication (Jay et al., 1981; Richardson and Westphal 1984; Samulski and Shenk 1988; Chang et
al., 1989; Janik et al., 1989; Ferrari et al., 1996), led to the development of a helper plasmid that
encodes necessary Ad genes (Ferrari et al., 1997; Grimm et al., 1998; Xiao et al., 1998) (Fig. 3).
This not only eliminated the need for infection with Ad and subsequent problems in purification
of contaminating Ad, but also improved rAAV yields over 40-fold. This was attributed to a
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controllable amount of helper Ad gene products, and freeing up of biochemical machinery since
Ad helper plasmids do not lead to Ad virus packaging and replication (Xiao et al., 1998).
Secondly, optimization of AAV rep and cap protein expression involved in replication and
packaging improved yields (Grimm et al., 1998; Xiao et al., 1998; Collaco et al., 1999), as rep
overexpression was found to limit capsid assembly (Fan and Dong 1997; Li, J. et al., 1997).
Lastly, novel purification methods such as heparin affinity chromatography for AAV2
(Clark et al., 1999), and iodixanol gradient centrifugation followed by anion-exchange
chromatography for all AAV serotypes (Zolotukhin et al., 2002; De Backer et al., 2011) has
replaced inefficient cesium chloride (CsCl) gradient centrifugation purification. Multiple CsCl
gradient centrifugations needed for in vivo rAAV preparations led to low yields and lack of
scalability. Moreover, aggregation of rAAV with Ad cellular proteins occurred in the presence of
CsCl, and toxicity of CsCl necessitated extensive dialysis post-centrifugation (Burova and Ioffe
2005). Iodixanol centrifugation, in comparison, eliminated aggregation of macromolecules and
did not require dialysis prior to subsequent chromatography purification (Zolotukhin et al.,
1999). Most importantly, rAAV vector preparations showed superior viral infectivity following
iodixanol compared to CsCl gradient purification (Zolotukhin et al., 1999).

Transduction of retinal pigmented epithelial (RPE) cells
The RPE is highly permissible for viral transduction which was achieved even in early
studies using Ad (Jomary et al., 1994; Li, T. et al., 1994; Li, T. and Davidson 1995). However,
immunogenicity and subsequent transient expression in RPE cells limited the in vivo use of
adenoviral gene vectors (Li, T. et al., 1994; Reichel et al., 1998). The prototypic AAV2 showed
efficient transduction and a greater safety profile than Ad (Ali et al., 1996; Grant et al., 1997).
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More importantly, longevity of expression was demonstrated up to 11 weeks post-injection
(Bennett et al., 1997).
Cloning and characterization of additional AAV serotypes led to development of
pseudotyped AAVs, where rAAV vectors express AAV2 rep proteins with cap proteins of a
different AAV serotype. All AAV serotypes (AAV1-9) developed thus far have demonstrated
efficient RPE transduction, with AAV2, 4, and 6 primarily transducing RPE over neural retina
(Lebherz et al., 2008; Beltran 2009; Boye, S. E. 2012). Ultimately, ease of RPE transduction led
to specific targeting of Rpe65 LCA patients for clinical trials and contributed to the success of
these trials.

Gene therapy for Rpe65 LCA: From pre-clinical to clinical trials
RPE65 plays a role in the production of visual chromophore 11-cis retinal necessary for
regeneration of photoactivatable rhodopsin (Redmond et al., 1998). Specifically, RPE65, an
isomerase present in the retinal pigmented epithelium, converts all-trans retinyl esters into 11-cis
retinyl esters (Fig. 1B). In LCA2, the primary defect is in RPE65, leading to dysfunctional
rhodopsin and phototransduction signaling. Photoreceptors show subsequent but delayed
degeneration, relative to early visual dysfunction in Rpe65-null mice and dogs. In Rpe65-null
mice, initial morphological abnormalities are observed at 7-15 weeks of age with outer segment
disorganization. Slow progressive loss of photoreceptors ensues with 70% of ONL remaining at
6-7 months, 50% of the ONL at 12-18 months, and 30% at 24 months of age (Redmond et al.,
1998; Gouras et al., 2002; Cideciyan 2010). Although significant photoreceptor loss does not
occur until about 12-18 months of age, ERG responses are abolished at 10 weeks of age
(Redmond et al., 1998). A similar trend is present in the Rpe65 Briard dog, where a naturally
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occurring homozygous 4-bp frameshift deletion was found. This mutation introduces a premature
stop codon that truncates two-thirds of the protein resulting in a nonfunctional protein (Veske et
al., 1999). At 5 weeks of age, Rpe65 dogs demonstrate abolished scotopic ERG responses and
low photopic responses despite a near normal retina with some outer segment disorganization
(Narfstrom et al., 2003). Photoreceptor cell loss begins at 7-18 weeks of age and is complete by 7
years of age in the peripheral retina (Wrigstad et al., 1992; Wrigstad et al., 1994; Hernandez et
al., 2010). These results show that in young Rpe65 mice and dogs, photoreceptor loss does not
correlate with the observed level of visual function loss (Cideciyan 2010).
This observation was confirmed with a mathematical model that predicts photoreceptor
function proportional to the product of the number of surviving photoreceptors and the length of
their outer segments in retinal degeneration (Machida et al., 2000), or approximately as the loss
of light sensitivity (in linear units) proportional to the square of ONL thinning (Jacobson et al.,
2005). In line with Rpe65 animal models, in vivo optical coherence tomography (OCT) studies of
Rpe65 LCA patients show areas of partially retained photoreceptors averaging about 60-65% of
normal photoreceptor thickness, which is greater than expected for the level of dysfunction at
both the fovea and rod-rich regions (Jacobson et al., 2005; Cideciyan 2010). In comparison, OCT
data from non-Rpe65 retinal degeneration patients demonstrated that photoreceptor loss was in
line with loss of visual function (Jacobson et al., 2007b; Jacobson et al., 2008a). This
characteristic of Rpe65 defects provides a therapeutic window of opportunity that led to
successful vision rescue in Rpe65 animal models and indicated Rpe65 LCA patients as good
candidates for gene therapy clinical trials.
Vision restoration was achieved with multiple AAV serotypes in the Rpe65-null mouse.
Treatment with AAV1 at 2 months of age or earlier led to a high success rate and restoration of

9

ERG a- and b-waves, whereas treatment at 1.5 to 2 years of age led to a low success rate and
restoration only of b-waves (Jacobson et al., 2005). In utero AAV1 treatment led to equal or
greater rescue of ERG responses than treatment at 2 months of age (Dejneka et al., 2004). These
studies indicate that early intervention benefits vision rescue even in Rpe65 slow degeneration.
Rescue of Rpe65-null mice was also achieved with AAV2 (Bennicelli et al., 2008), the serotype
primarily used in rescue of the Rpe65 canine model. Fully functional vision rescue was achieved
in the Rpe65 canine model as measured through 11-cis retinal regeneration, ERGs, pupillary
light responses, cortical activity, and vision-guided navigation following treatment at 3-5 months
of age (Acland et al., 2001; Aguirre et al., 2007), with stability of rescue up to 3 years postinjection (Acland et al., 2005). Safety of AAV2-Rpe65 in nonhuman primates was also
demonstrated prior to advancement into clinical trials (Jacobson et al., 2006).
Three independent phase I clinical trials demonstrated patient safety following delivery
of AAV2-RPE65 to young adult Rpe65-LCA patients, with no significant occurrence of humoral
responses nor presence of viral vectors in saliva, tears, or peripheral blood (Bainbridge et al.,
2008; Hauswirth et al., 2008; Maguire et al., 2008). More importantly, the studies demonstrated
treatment efficacy in multiple measurements of visual function. In one study, 3 of 3 patients
showed improved visual acuity that lasted at least 1.5 years post-treatment (Maguire et al., 2008;
Maguire et al., 2009). Despite unimproved visual acuity in the other two studies, improvements
in vision were observed through more sensitive visual function assays. Treated eyes
demonstrated improved light sensitivity as measured through full-field sensitivity tests
(Hauswirth et al., 2008; Maguire et al., 2009), a psychophysical test designed to assay vision in
patients with severe vision loss (Roman et al., 2007). Secondly, transient pupillary light reflex
(TPLR) responses which demonstrate transmission of visual information from the retina to the
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brainstem, were elicited at lower light intensities post-treatment than at baseline, demonstrating
enhanced light sensitivity (Cidecian et al., 2008; Maguire et al., 2008, 2009). Three year posttreatment follow-up showed that patients also interestingly developed a pseudofovea, an
extrafoveal area with improved visual acuity and light sensitivity that therefore functioned as a
central fixation locus (Jacobson et al., 2012).

Advancements in AAV for photoreceptor targeting
Rapid and efficient transduction of photoreceptors
Although first generation AAV2 provide high transduction of retinal pigmented
epithelium in Rpe65 clinical trials, AAV2 shows limited transduction of photoreceptors (Grant et
al., 1997; Ali et al., 1998). Greater photoreceptor transduction has been achieved with AAV5, 7,
and 8 over AAV2 (Yang et al., 2002; Allocca et al., 2007; Lebherz et al., 2008). The standout
pseudotype for photoreceptor targeting has been AAV8 following its isolation from the rhesus
monkey (Gao et al., 2002). AAV8 demonstrated greater photoreceptor transduction at early postinjection times, as rapid as 5 days post-injection compared to 1-2 weeks post-injection in AAV2
and 5. Additionally, at the plateau of expression, AAV8 provided significantly higher
photoreceptor transduction than AAV5 (Natkunarajah et al., 2008). AAV7 demonstrated slightly
higher or similar photoreceptor transduction to AAV8 at 4-5 weeks post-injection (Allocca et al.,
2007; Lebherz et al., 2008), although early photoreceptor transduction has not been examined.
The robust and rapid kinetics of photoreceptor transduction has set AAV8 apart from other
recent AAV serotypes, providing an essential characteristic for rapid retinal degeneration often
seen with photoreceptor gene defects. While AAV7 and 8 provide a clear advantage in
photoreceptor tropism, the route of viral particle binding and entry has not been elucidated for
11

these serotypes. In contrast, it is known that AAV2 binds heparan sulfate and AAV5 sialic acid
as the primary receptor for attachment (Summerford and Samulski 1998; Walters et al., 2001).
Elucidating the receptor for AAV7 and 8 may shed light on the high photoreceptor tropism and
potential methods to enhance photoreceptor targeting.
Early onset of expression is also achieved with self-complementary AAV (scAAV),
which forms a double-stranded DNA (dsDNA) conformation that bypasses second-strand
synthesis required by conventional single-stranded AAV (ssAAV) prior to transcription. scAAV
is generated by mutating the terminal resolution site (trs) in the 5’ ITR in the wildtype AAV
construct, which leads to read-through and formation of a dimeric inverted repeat structure with
two complete ITRs at the ends and a mutated ITR in the middle during replication (Mccarty et
al., 2001; Mccarty et al., 2003; Mccarty 2008) (Fig. 4). Expression initiates as early as postinjection (pi) day 2-3 with scAAV8 and scAAV2, as compared to pi day 5-7 in ssAAV8 and pi
day 14 in ssAAV2 (Yokoi et al., 2007; Natkunarajah et al., 2008). In addition, scAAV provided
higher transduction efficiency over ssAAV for AAV2, 5, and 8, at 5 weeks post-injection when
maximal transduction has occurred (Yokoi et al., 2007; Natkunarajah et al., 2008). The increased
efficiency of scAAV is partially attributed to degradation of ssAAV during the single-stranded
phase. Further characterization of ss- and scAAV processing is needed however, as opposing
studies report a transient instability of both ssAAV and scAAV following cell entry (Mccarty
2008).
Another advancement that improves stability of viral particles upon cell entry is AAV
capsid mutations. Studies examining intracellular trafficking of rAAV revealed that
ubiquitination and proteasomal degradation of viral particles was one route of decreased
transduction efficiency (Yan et al., 2002; Zhong et al., 2007; Zhong et al., 2008a). Since
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ubiquitination of cellular and viral proteins is often modulated through phosphorylation of serine
and tyrosine residues, mutagenesis of surface-exposed tyrosine residues of capsid proteins were
reasoned to protect against viral particle degradation. As hypothesized, tyrosine capsid mutants
showed greater transduction over their wildtype capsid counterparts (Petrs-Silva et al., 2009;
Ryals et al., 2011). Recently developed threonine capsid mutations are also showing similar
effects to tyrosine mutations (Boye, S.E. 2012).

Current limitations in AAV-mediated gene therapy
Despite advantages in the safety and efficacy of AAV, some limitations remain with its
use. The greatest hindrance is the limitation in transgene size of 4.7 kb for single-stranded AAV
and 2.3 kb for self-complementary AAV. This size restriction, which must include both gene
promoter and transgene, stems from the natural size of the wildtype AAV genome between two
inverted terminal repeats (ITRs). It prevents delivery of LCA gene Cep290 (7.4 kb), and scAAV
packaging of Crb1 (4.2 kb), Gucy2d (3.3 kb), and Rpgrip1 (3.8 kb). Attempts at pushing beyond
the packaging capacity showed that above 5.2 kb, vector genomes were truncated at the 5’ end
(Dong et al., 2010; Wu, Z. et al., 2010). A slight improvement to 6.0 kb was obtained by
eliminating the VP2 capsid protein, one of three capsid proteins normally needed for viral
encapsulation (Grieger and Samulski 2005). In contrast to these studies, one group demonstrated
intact viral genome packaging and in vivo transduction of an 8.9 kb transgene with AAV5
(Allocca et al., 2008). Despite this controversy, the packaging capacity of AAV is in stark
contrast to the 36 kb capacity of Ad (Beltran 2009).
Another limitation in AAV retinal gene therapy is the cumbersome and delicate
administration of viral solution into the subretinal space (Fig. 5), which is actually a non-
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physiological potential space between the retina and RPE. In patients, the procedure requires a
vitrectomy followed by a puncture through the retina (retinotomy). In addition to transient
detachment and local damage of the retina, disadvantages of subretinal injection into patients
with retinal degeneration are two-fold. First, non-uniform degeneration makes it difficult to
identify the best area to introduce the virus. Secondly, the degenerating retina is extremely
fragile and susceptible to retinal tears (Maguire et al., 2008).
In contrast, intravitreal injection (Fig. 5) is a safe and relatively easy outpatient procedure
routinely conducted to deliver anti-VEGF drugs to wet AMD patients. Although transduction of
retinal ganglion cells following intravitreal injections have been demonstrated with AAV2, 8,
and 9 (Harvey et al., 2002; Lebherz et al., 2008; Giove et al., 2010; Yin et al., 2011), efficient
transduction of outer retinal photoreceptors is hindered by the inner limiting membrane (ILM)
(Dalkara et al., 2009). The ILM is a basement membrane composed of various extracellular
matrix proteins, several of which have been found to mediate AAV2, 8, and 9 binding and
accumulation at the vitreoretinal junction (Akache et al., 2006; Kolstad et al., 2010). The ILM is
essential in retinal development but is dispensable in adults, as its removal is commonly
conducted in macular hole surgeries. Importantly, this barrier was partially overcome with coadministration of proteolytic enzymes with AAV, a potential therapeutic application for
transducing the outer retina via an intravitreal injection (Dalkara et al., 2009). However, further
progress is needed to improve upon the efficiency of outer retinal transduction achieved in this
study. Another advancement found to transduce photoreceptor following intravitreal delivery is
AAV triple tyrosine capsid mutant, which interestingly transduced foveal cone photoreceptors in
non-human primates (Boye, S.E. 2012). This is a particularly desirable development as foveal
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thinning was a complication in several Rpe65 LCA patients receiving viral gene therapy, likely
arising from foveal detachment following subretinal injections (Jacobson et al., 2012).

Targeting photoreceptor gene defects: Aipl1 as a candidate gene
Overview
Since Rpe65 LCA clinical trials, there has been a push to target additional genetic defects
associated with inherited retinal degeneration. Recent and continuing advancements in AAV
vectors improved photoreceptor transduction, allowing for correction of photoreceptor defects.
Treatment of defects in Aipl1, a chaperone protein for the phototransduction protein
phosphodiesterase 6 (PDE6), shows potential for entry into clinical trials. Although Aipl1 is
mainly associated with LCA, the most severe of IRDs, it has also been linked to CORD and RP
which show later onset and slower progression of vision loss (Fig. 7), indicating a subset of Aipl1
patients who can benefit from gene replacement therapy.
Multiple Aipl1 mouse models exist allowing for pre-clinical gene therapy studies. The
Aipl1-null mouse models Aipl1-LCA, whereas the Aipl1 hypomorph mouse, with a 75-80%
reduction in protein levels, models a slow progressing retinal degeneration. Additionally, our
novel P351Δ12 Aipl1 mutant mouse phenocopies Aipl1-CORD. Successful vision rescue
following AAV-mediated gene replacement was achieved in several of these mouse models,
showing the potential to correct IRDs associated with Aipl1 defects.
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Aryl hydrocarbon receptor interacting protein-like 1 (Aipl1) defects
Aryl hydrocarbon receptor interacting protein-like 1 (AIPL1) is a 384 aa protein found in
the pineal gland and retina, where it is specifically expressed in early and mature rod and cone
photoreceptors (Van Der Spuy et al., 2003; Kirschman et al., 2010). AIPL1 is a member of the
immunophilin FK506 binding protein (FKBP) family. Similar to several multi-domain
immunophilins, AIPL1 contains an N-terminal peptidyl-prolyl cis-trans isomerase (PPIase)-like
domain and three C-terminal tetratricopeptide repeat (TPR) domains. Primate AIPL1 isoforms
also contain a C-terminal proline-rich region referred to as the hinge region, an area of unknown
function or significance (Fig. 6A).
Aipl1-null and hypomorphic mice, which express 20-25% of wildtype AIPL1 levels (Liu
et al., 2004), show a specific and dramatic reduction of all rod PDE subunits despite unaltered
mRNA levels (Liu et al., 2004; Ramamurthy et al., 2004), indicating the role of AIPL1 in posttranscriptional processing of rod PDE6 holoenzyme. Further work has elucidated that AIPL1 is
required for the stability of rod PDE6 subunits and assembly of the PDE6αβγ2 complex, and that
AIPL1 specifically interacts with the α catalytic subunit (Kolandaivelu et al., 2009). The
interaction between AIPL1 and PDEα subunit is not surprising due to yeast two-hybrid studies
showing the interaction of AIPL1 with farnesylated proteins (Ramamurthy et al., 2003).
However, whether AIPL1 acts to facilitate the farnesylation reaction of PDEα, folding of PDEα
or oligomerization of PDE6αβγ2 remains unknown, all of which may enhance PDE6 stability and
assembly. The site of PDEα interaction for AIPL1 chaperone activity has also yet to be
elucidated. The role of AIPL1 in cone photoreceptors is currently being elucidated, as loss of
AIPL1 leads to rapid rod and cone degeneration associated with LCA and modeled in the Aipl1null mouse. Loss of cone photoreceptors is not simply secondary to massive rod loss, as
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demonstrated by the cone-specific elimination of AIPL1 leading to loss of photopic ERGs and
cone death (Kirschman et al., 2010).
Defects in Aipl1 are associated with autosomal recessive Leber congenital amaurosis
(LCA4), in approximately 7% of LCA cases (Sohocki et al., 2000b). Several reports also link
Aipl1 defects to autosomal dominant cone-rod dystrophy (adCORD), juvenile retinitis
pigmentosa (RP), non-early onset RP, and later onset retinal degeneration (Sohocki et al., 2000b;
Vallespin et al., 2007; Walia et al., 2010; Jacobson et al., 2011) (Fig. 6C, Fig. 7).
LCA is the most severe of retinal degenerations, with severe visual impairment within the
first few months of life and absent or severely reduced rod- and cone-mediated ERGs. RP
patients typically present with night blindness as the first visual impairment alongside normal
visual acuity, with somewhat varied progression and severity. Although clear diagnostic criteria
are not universally agreed upon, juvenile, early- or childhood-onset RP typically denote
symptoms initiating from 1 year to 10 years of age, whereas non-early or late-onset RP typically
refers to initiation after 10 years of age. CORD patients present with impaired central vision and
decreased visual acuity with progressive loss of peripheral vision, but retain measurable ERGs
for several years. The case of Aipl1 associated with later onset retinal degeneration was
described with slower onset and progression than LCA or juvenile RP (Jacobson et al., 2011).
These cases of non-LCA IRDs associated with Aipl1 (Fig. 6C) indicate a larger window of
opportunity for treatment relative to Aipl1-LCA. Additionally, evidence of ERG responses and
photoreceptor survival in some Aipl1 patients demonstrate salvageable photoreceptor cells (Fig.
6C) (Jacobson et al., 2011; Pennesi et al., 2011; Testa et al., 2011).
The most common Aipl1 defect in over 60% of Aipl1-LCA cases is truncation mutation
W278X (Dharmaraj et al., 2004; Hanein et al., 2004) leading to an unstable and degraded protein
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(Ramamurthy et al., 2003), which is mimicked in the Aipl1-null mouse model. However, point
mutations and small base pair deletions in the PPIase-like and TPR domains of AIPL1 are also
prevalent in the patient population. Several point mutations such as A197P and C239R retain
functionality in vitro in interacting with and processing farnesylated proteins despite
compromised folding and stability (Ramamurthy et al., 2003). Whether some mutations translate
functional or partially functional protein is an important clinically relevant question. The Aipl1
hypomorphic mouse mimics such a hypothetical state. In addition, a reported patient mutation
P351Δ12 in the C-terminal proline-rich hinge region retains partial functionality in vivo as
demonstrated in our hAipl1 transgenic mouse model (Chapter 3). Although the rarity of Aipl1
cases severely limits any genotype-phenotype correlations that can be made, reports of Aipl1 CORD and -RP (Fig. 6C), combined with the idea that some mutations may retain functionality,
indicate the potential of a subset of Aipl1 patients who may benefit from gene therapy.

Pre-clinical rescue studies of Aipl1 defects
AAV-mediated gene replacement studies have successfully rescued vision in Aipl1
hypomorphic mice (Tan et al., 2009; Sun et al., 2010) which express 20-25% of wildtype levels
of mAIPL1. Aipl1 hypomorphic mice show slow degeneration, with photoreceptor cell loss
beginning at 3 months of age and reduced to half of the normal outer nuclear layer (ONL)
thickness by 8 to 10 months of age (Liu et al., 2004). In AAV-rescue studies, Aipl1 hypomorph
degeneration was expedited with light damage (Tan et al., 2009), with the 50% reduction in ONL
thickness accelerated to 6.25 months of age. A second strategy was used in Sun et al., 2010,
where Aipl1 hypomorphs were crossed with Aipl1-null mice to generate F1 “Aipl1hypo” offspring,
which exhibit a 75% reduction in ONL thickness by 11 months of age. These Aipl1 hypomorph
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mouse models were successfully treated with single-stranded AAV2 (Tan et al., 2009) and
AAV5 (Sun et al., 2010).
In contrast, AAV2 and AAV5 were unable to rescue photoreceptor structure and function
in Aipl1-null mice (Sun et al., 2010), further confirming the subpar efficiency of AAV2 and 5 in
photoreceptor targeting. Two independent Aipl1-null models recapitulate severe LCA with early
visual defects accompanied by rapid degeneration, although one model demonstrates 13% of
surviving photoreceptors in the peripheral retina at P60 (Dyer et al., 2004) whereas a second
shows complete photoreceptor loss by P24 (Ramamurthy et al., 2004). Vision rescue was
achieved in the former Aipl1-null model with AAV8 (Tan et al., 2009; Sun et al., 2010).
However, more recent developments in AAV may improve vision rescue effects in the Aipl1-null
mouse, which requires rapid and robust transduction to combat the extremely rapid retinal
degeneration beginning at P8 and complete by P24.

Objective
The combination of recent developments in AAV increase the capability to rescue rapid
retinal degeneration associated with photoreceptor gene defects. One such photoreceptor defect
is Aipl1, in which our Aipl1-null mouse model shows the most rapid retinal degeneration of all
mouse models. Study 1 is proof-of-principle that advancements in AAV significantly improve
photoreceptor transduction over first generation AAV vectors, which were sufficient for slow
retinal degeneration. Vision rescue achieved in Aipl1-null mice using self-complementary capsid
mutant AAV8 is compared to first generation single-stranded AAV8 through functional,
morphological, and biochemical assays. In addition, clinical reports of Aipl1 patients with
relatively slower forms of retinal degeneration relative to LCA indicate that a population of Aipl1
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patients may potentially benefit from gene replacement therapy. Study 2 provides a mouse model
of an Aipl1 patient mutation showing a cone-rod dystrophy phenotype, demonstrating that Aipl1
mutations are potentially amenable to gene replacement therapy. Chapter 4 concludes with a
summary of findings and the implications of gene replacement therapy for inherited retinal
degeneration associated with Aipl1.

20

Figures
Fig. 1

Fig. 1. The neural retina and RPE. (a) The laminated neural retina is made up of three cellular
layers: the outer nuclear layer (ONL) is rod and cone photoreceptor nuclei; inner nuclear layer
(INL) is composed of bipolar, horizontal, and amacrine cells; and the retinal ganglion cell (RGC)
layer of which the axons form the optic nerve. The retinal pigmented epithelium (RPE) is located
between photoreceptor outer segments (OS) and the vascular choroid, and is essential in the
visual retinoid cycle. (b) The visual retinoid cycle involves enzymes in both the RPE and PR for
regeneration of 11-cis retinal that upon photoisomerization, leads to activation of opsin and
initiation of visual signal transduction. Abbreviations: ATP-binding cassette transporter, retinaspecific (ABCR), retinol dehydrogenase (RDH), interphotoreceptor retinoid binding protein
(IRBP), cellular retinoid binding protein (CRBP), lecithin retinol acyltransferase (LRAT), retinal
pigment epithelium-specific protein, 65 kDa (RPE65), cellular retinaldehyde binding protein
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(CRALBP), retinol binding protein 4 (RBP4). Adapted from (Besch et al., 2003; Kuksa et al.,
2003).
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Fig. 2

Fig. 2. Genes associated with inherited retinal degeneration (IRD). Each IRD is associated
with defects in numerous genes, some of which are also associated with other IRDs (in
overlapping areas). LCA, the most severe of IRDs, has over 16 associated genes, with recent
defects in Cabp4 (2010), Iqcb1 (2011), and Kcnj13 (2011) reported. Apart from these select few
with unknown function, most genes associated with LCA have known mechanisms of
dysfunction mainly in phototransduction (navy font), ciliary transport (pink), and visual retinoid
cycle (maroon). Other important classes of dysfunction are retinal development and structure
23

(dark green), photoreceptor OS structure (purple), and ion channels (light green). RP, on the
other hand, is linked to over 50 genes, in which many have unknown functions. Genetic testing is
not routinely conducted in CORD patients and it is predicted that many genes remain
unidentified. Symbols: genes associated with autosomal dominant disease are *adLCA, “adRP,
^adCORD. Adapted from (Berger et al., 2010).
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Fig. 3

Fig. 3. Production of AAV. Original AAV production involved co-transfection of a plasmid
with the transgene of choice cloned between two 145-bp inverted terminal repeats (ITRs) and a
mini plasmid encoding necessary AAV rep and cap genes, alongside adenovirus (Ad) infection
into 293 cells. Subsequent purification of Ad particles from rAAV preparations was required
with this method. Understanding of the role of Ad genes in AAV replication substituted Ad
infection with a helper plasmid encoding Ad genes E1a, E1b, E2a, and VA. Adapted from
(Goncalves 2005).
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Fig. 4

Fig. 4. Single-stranded and self-complementaryAAV. Replication of AAV particles initiates at
the 3’ ITR (step 1) which acts as a primer for host DNA polymerase. Following elongation, the
5’ ITR is duplicated (step 2), and this duplex ITR is isomerized to a double-hairpin conformation
(step 3) to create a new primer site for re-initiation of DNA synthesis (step 4). While the 3’ ITR
is elongated and daughter strand displaced (ssAAV genome) (step 5m, 6m), rep 78/68 binds and
nicks at the terminal resolution site (trs) of the ITR before being reached by DNA elongation
occurring at the other end. Following elongation at the opposite end, the resultant duplex
monomer (top structure following step 6m) recreates the template for isomerization in step 3.
scAAV genomes are produced through deletion of one trs site from one ITR, such that the rep
protein no longer creates the essential nick. The replication complex copies through the hairpin,
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producing a double-stranded inverted repeat, with a wildtype ITR at both ends and a mutated
ITR in the middle (structure following step 6d). The dimeric inverted repeat undergoes normal
replication initiating at any of the wildtype ITRs (steps 7d-9d), with displacement and generation
of the scAAV genome, which is an inverted repeat with a complete ITR at both ends and a
mutated ITR in the middle. Adapted from (Mccarty 2008).

27

Fig. 5

Fig. 5. Subretinal and intravitreal routes of intraocular gene delivery. Subretinal
administration deposits viral solution between the retinal pigmented epithelium (RPE) and
photoreceptors, ideal for transduction of either of these cell types. However, a puncture through
the retina is required in subretinal injections leading to local damage and temporary local retinal
detachment. Intravitreal injections deposit viral solution in the vitreal space behind the lens and
does not cause retinal damage or detachment. Adapted from (Colella et al., 2009).
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Fig. 6

Fig. 6. Aipl1 domains and function. Aipl1 (a) contains a FKBP-like domain, 3 tetracopeptide
repeat (TPR) domains, and a C-terminal region present only in primate isoforms. (b) Three
different patient mutations (orange, blue, red arrows and underline) disrupt a repeating PxxP
motif (black underline) present in the C-terminal proline-rich hinge region (grey boxes). (c)
Aipl1 has been sporadically associated with inherited retinal degenerations outside of LCA, two
of such cases associated with hinge region mutation, P351Δ12.
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Fig. 7

Fig. 7. Spectrum of IRD associated with Aipl1. Aipl1 is associated mainly with Leber
congenital amaurosis (LCA), a rapid rod and cone dystrophy on the most severe end of the
spectrum of inherited retinal degenerations (IRD), with severe visual deficits and loss of ERGs
within the first few months of life. Additionally, Aipl1 mutations were found in patients with
cone-rod dystrophy (CORD) and juvenile early onset-retinitis pigmentosa (RP) in a few isolated
cases. CORD and RP show later onset and slower progression, with cone- and rod-mediated
visual deficits, respectively, presenting as the first visual symptoms.
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Chapter 2
Gene replacement therapy for Aipl1-null mice, a model of severe Leber
congenital amaurosis
Abstract
Defects in the photoreceptor specific gene aryl hydrocarbon receptor interacting proteinlike 1 (Aipl1) are associated with Leber congenital amaurosis (LCA), a childhood blinding
disease with early-onset retinal degeneration and vision loss. Furthermore, Aipl1 defects are
characterized at the most severe end of the LCA spectrum. The rapid photoreceptor degeneration
and vision loss observed in the LCA patient population is mimicked in a mouse model lacking
AIPL1. Using this model, we evaluated if gene replacement therapy using recent advancements
in adeno-associated viral vectors (AAV) provides advantages in preventing rapid retinal
degeneration. Specifically, we demonstrated that the novel self-complementary Y733F capsid
mutant AAV2/8 (sc-Y733F-AAV2/8) provided greater preservation of photoreceptors and
functional vision in Aipl1 null mice compared to single-stranded AAV2/8. The benefits of scY733F-AAV were evident following viral administration during the active phase of retinal
degeneration, where only sc-Y733F-AAV treatment achieved functional vision rescue. This
result was likely due to higher and earlier onset of Aipl1 expression. Based on our studies, we
conclude that the sc-Y733F-AAV2/8 viral vector, to date, achieves the best rescue for rapid
retinal degeneration in Aipl1 null mice. Our results provide important considerations for viral
vectors to be used in future gene therapy clinical trials targeting a wider severity spectrum of
inherited retinal dystrophies.
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Introduction
Inherited retinal dystrophies are a large group of clinically and genetically diverse
conditions estimated to affect 1 in 3000 people (Daiger et al., 2007; Sun et al., 2010). The
earliest and most severe form is Leber congenital amaurosis (LCA), which is estimated to
account for ≥ 5% of inherited retinopathies (Schappert-Kimmijser et al., 1959; Koenekoop
2004). LCA is diagnosed with clinical findings of severely impaired visual function shortly after
birth, sluggish pupillary responses, nystagmus, and an absent or markedly reduced
electroretinogram (ERG). Patients with LCA may also exhibit fundus changes, photophobia, the
occulodigital sign, keratoconus, and cataract (Schappert-Kimmijser et al., 1959; Foxman et al.,
1985). To date, LCA is associated with mutations in at least 15 different genes expressed in
either photoreceptor or retinal pigment epithelium (RPE) cells (Human Gene Mutation Database,
http://www.hgmd.org, April 12, 2011). Clinical heterogeneity within LCA had long been
recognized (Noble and Carr 1978; Foxman et al., 1985; Schroeder et al., 1987; Fulton et al.,
1996), but more recent genotype-phenotype correlation studies showed subtle but important
differences in fundus appearance, visual acuity, and disease progression (Perrault et al., 1999;
Hanein et al., 2004; Galvin et al., 2005).
Greater understanding of the molecular basis of genetic defects in inherited retinopathies
coupled with developments in viral-mediated gene delivery have led to potential therapies for
some retinal dystrophies, which were a previously untreatable group of diseases. Defects in
retinal pigment epithelium-specific protein 65 kDa (RPE65) are associated with autosomal
recessive retinitis pigmentosa and LCA. In multiple animal models, mutations in RPE65 lead to
vision loss but photoreceptor neurons develop normally and survive for an extended period
(Wrigstad et al., 1994; Redmond et al., 1998; Pang et al., 2005). This characteristic of RPE65
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mutations was crucial in successful preclinical trials in multiple animal models (Acland et al.,
2001; Chen et al., 2006; Pang et al., 2006; Bennicelli et al., 2008). Although patients with RPE65
mutations exhibit greater photoreceptor degeneration than animal models, optical coherence
tomography (OCT) demonstrated preservation of the photoreceptor cell layer that is greater than
predicted from the level of visual dysfunction (Jacobson et al., 2005). These findings indicated
that there is a window of time for therapeutic intervention, which made RPE65 patients an ideal
initial target for gene therapy trials. Landmark clinical trials which delivered exogenous RPE65
gene using the adeno-associated virus 2 (AAV2), showed visual improvements in patients
(Bainbridge et al., 2008; Cideciyan et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008;
Cideciyan et al., 2009; Simonelli et al., 2010), and are paving the way for gene therapy for
inherited retinal degenerative diseases associated with other genetic defects.
On the other end of the disease spectrum are mutations linked to LCA that cause rapid
photoreceptor degeneration. The degeneration is pronounced when associated with defects in
Aryl hydrocarbon receptor interacting protein-like 1 (Aipl1). AIPL1 is a 386 amino acid protein
that belongs to the FK506 binding protein (FKBP) family of chaperone proteins (Sohocki et al.,
2000a), and is expressed early and specifically in photoreceptors (Hendrickson et al., 2008).
AIPL1 is crucial for the stability of rod phosphodiesterase 6 (PDE6), an enzyme that is involved
in cyclic GMP phototransduction signaling (Liu et al., 2004; Ramamurthy et al., 2004;
Kolandaivelu et al., 2009). Although the role in cone photoreceptors is not fully understood,
AIPL1 is required for cone function and survival (Kirschman et al., 2010). In the Aipl1 null
mouse, both rod and cone electroretinogram (ERG) responses are absent and complete
photoreceptor cell loss occurs by 3 weeks of age (Ramamurthy et al., 2004). Patients with Aipl1
mutations, implicated in 5-7% of LCA cases and several incidences of juvenile retinitis

33

pigmentosa and cone-rod dystrophy (Sohocki et al., 2000b), have a stable but drastically reduced
visual acuity by the first decade in life, ranging from 20/200 to no light perception (Galvin et al.,
2005; Simonelli et al., 2007; Walia et al., 2010). The level of photoreceptor survival in patients
has not been extensively examined, but two recent studies found photoreceptors in OCT scans of
patients with mutations in Aipl1 (Jacobson et al., 2011; Testa et al., 2011). While the window of
therapeutic opportunity is smaller in Aipl1 defects due to rapid photoreceptor degeneration, these
findings highlight the possibility that patients with Aipl1 defects could benefit from early gene
replacement therapy.
Two important proof-of-concept studies used adeno-associated viral (AAV)-mediated
gene replacement therapy in the Aipl1 hypomorphic and null mouse (Tan et al., 2009; Sun et al.,
2010). These were the first studies to show that Aipl1 replacement could restore functional rod
and cone PDE6 and prevent the loss of photoreceptors. Since these two studies, advancements in
virology resulted in AAV vectors with increased transduction efficiency and shortened onset of
expression. The first development was self-complementary AAV, which produces a double
stranded gene vector that is more stable and eliminates the need for second-strand DNA
synthesis (Mccarty et al., 2001). These characteristics conferred both earlier onset and increased
transduction efficiency compared to single-stranded AAV (Natkunarajah et al., 2008; PetersenJones et al., 2009; Kong et al., 2010). The second development was mutations of surfaceexposed tyrosine residues on the viral capsid. The resultant decrease in capsid tyrosine
phosphorylation reduces ubiquitination of viral particles and subsequently improves nuclear
transport and transduction efficiency (Zhong et al., 2007; Zhong et al., 2008b).
The aim of this study was to utilize these developments in AAV vectors in order to
maximize therapeutic effects of gene replacement therapy for rapid retinal degeneration.
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Specifically, we assessed the efficiency of gene replacement therapy using single-stranded
AAV2/8 (ssAAV) or the novel self-complementary Y733F tyrosine capsid mutant AAV2/8
(scAAV) delivering the human Aipl1 gene. In these studies, we first assessed the onset and
efficiency of gene expression achieved with each virus in wild-type retina. We further evaluated
the level of vision rescue that ssAAV or scAAV provides to Aipl1-/- mouse, a model of rapid
retinal degeneration, following treatment at an early and later stage of photoreceptor
degeneration.
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Materials and Methods
Animals
Aipl1 knockout mice were generated and characterized previously (Ramamurthy et al., 2004).
Aipl1 knockout mice and wild-type used in this study are in a mixed C57Bl/129sv background.
Mice were maintained under 12-h light / 12-h dark light cycles. All experiments involving
animals were approved by the Institutional Animal Care and Use Committee at West Virginia
University.
Generation of recombinant AAV vectors
Full-length human Aipl1 was amplified from human retinal cDNA using Aipl1 specific primers
and cloned into the multiple cloning site of the parental pAAV-RKp-zsGreen vector to generate
the pAAV-RKp-hAipl1 plasmid, which was used to produce the ssAAV2/8-RKp-hAipl1 viral
vector as described in Sun et al (Sun et al., 2010). RKp-hAipl1 was amplified from pAAV-RKphAipl1 with primers that engineered flanking Kpn-I and Eag-I sites, and cloned into the selfcomplementary AAV packaging vector, to generate the SC-RKp-hAipl1 plasmid. This plasmid
was used to produce the scAAV2/8-Y733F-RKp-hAipl1 viral vector. The self-complementaryY733F-AAV2/8 pseudotyped viral vector was generated as described previously, using the
AAV8 capsid protein with Y733F surface-exposed tyrosine residue mutation (Zolotukhin et al.,
2002; Zhong et al., 2008b). All polymerase chain reaction (PCR) amplifications were performed
with Phusion GC DNA polymerase master mix (Finnymes, Thermo Scientific, Lafayette, CO,
USA), following manufacturer instructions for cycling conditions. All plasmids were sequenced
with the Big Dye Terminator ready reaction kit (Perkin Elmer, Waltham, MA, USA).
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Subretinal injection
Aipl1-/- mice injected at postnatal day 2 (P2) were anesthetized by chilling on ice. P10 Aipl1-/mice and P14 wild-type mice were placed under general anesthesia with an intraperitoneal
injection of ketamine (90 mg kg-1) / xylazine (9 mg kg-1) and received a drop of dilation solution,
consisting of a 1:1 mixture of tropicamide (1%, Alcon, Fort Worth, TX, USA) : phenylephrine
hydrochloride (2.5%, Bausch and Lomb, Tampa, FL, USA). For injection into mice prior to
eyelid opening, an incision was made along the natural future eyelid line with surgical vannas
scissors. A small incision was then made in the sclera just outside the pupillary margin with a 36gauge needle. Viral solution was injected into the subretinal space using a pulled glass pipette
attached to a pneumatic injector (MINJ-PD, Tritech Research, Los Angeles, CA, USA) using a
transcorneal approach (Matsuda and Cepko 2004). Self-complementary and single-stranded
AAV solutions were titer matched to 1.2x1013 viral particles per ml by diluting with phosphate
buffered saline (PBS). Each animal received 1.0 µl of AAV in the right eye, and no injection in
the untreated contralateral eye. Visualization during injection was aided by the addition of 0.1%
fluorescein (100 mg ml-1 AK-FLUOR, Alcon, Fort Worth, TX, USA) to the viral solutions.
Electroretinographic (ERG) analysis
Mice were dark-adapted overnight prior to testing. Eyes were topically dilated with a 1:1 mixture
of tropicamide: phenylephrine hydrochloride. For ERG testing, mice were placed on a heated
platform with continuous flow of isoflurane anesthesia through a nose cone (1.5% isoflurane
with 2.5 liters per min (lpm) oxygen flow rate). A reference electrode was placed subcutaneously
in the scalp. ERG responses were recorded from both eyes with silver wire electrodes placed on
each cornea, with contact being made with a drop of hypromellose solution (2% hypromellose in
PBS) (Gonioscopic Prism Solution, Wilson Ophthalmic, Mustang, OK, USA). Rod dominated
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responses were elicited in the dark with flashes of LED white light at increasing flash intensities.
Light-adapted cone responses were elicited in the presence of a 41 cd/m2 rod-desensitizing white
background light with 2.5 cd · s/m2 LED white light flashes. ERGs were performed on the UTAS
Visual Diagnostic System with BigShot Ganzfeld with UBA-4200 amplifier and interface, and
EMWIN 9.0.0 software (LKC Technologies, Gaithersburg, MD, USA).
Vision-dependent behavioral assay
Morris water maze assay to test for visual dependent behavior was performed as described in
Pang et al (Pang et al., 2008). Mice were tested in a dim-lit room at 1.5 to 2.0 lux. Briefly, the
task involved swimming in a 4 foot diameter water pool to an escape platform marked with a
flag as a visual guidance cue. The time to reach the escape platform was recorded. The escape
platform was washed between each trial to eliminate non-vision guided cues. Mice were trained
to this task for 3 days, consisting of 5 trials each day. During this training period, the escape
platform was stationary and the drop-off location of the mouse differed for each trial. On the 4th
training day, the escape platform was moved to a different location in each trial. On the test day,
day 5, the escape platform was also moved to a different location in each trial. However, to
control for differences in swimming distances, the platform locations were kept constant for
every mouse tested across all treatment groups. The reported times were taken from this final test
day as group average times.
Immunoblotting, immunohistology, and morphometric analysis
Mice were euthanized by CO2 inhalation and eyes were enucleated. For immunoblots, flash
frozen retinal samples dissected from enucleated eyes were sonicated in 6 M urea buffer (6 M
urea, 4% sodium dodecyl sulfate (SDS), 0.5 M Tris pH 6.8, 10 mg/ml DTT). Protein
concentrations were estimated using a NanoDrop spectrophotometer (Thermo Scientific). 100 µg
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total protein samples were resolved on 10% resolving SDS-polyacrylamide gel, and transferred
onto polyvinylidene difluoride membranes (Immunobilon-FL, Millipore, Billerica, MA, USA).
Membranes were blocked with blocking buffer (Rockland Inc., Gilbertsville, PA, USA) for 30
min at room temperature, and incubated with the indicated primary antibodies. Blots were
washed in PBST (Phosphate buffered saline, 137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4·7H2O, 1.4 mM KH2PO4, with 0.1% Tween-20) twice for 20 min and incubated in
secondary antibody, goat anti-rabbit IRDye 680 (LI-COR Biosciences, Lincoln, NE, USA) for 30
min at room temperature. After 3 washes with PBST, membranes were scanned using the
Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA), and bands
quantified using Odyssey Infrared Imaging System software.
For immunohistochemical studies, eyes were immersed in 4% paraformaldehyde fixative
for 15 min prior to removal of the anterior segments and lens. Eyecups were fixed for an
additional 4 h, washed in PBS (Phosphate buffered saline) for 20 min, incubated in 10%
sucrose/PBS for 1 h at room temperature, and transferred to 20% sucrose/PBS for overnight
incubation at 4°C. Eyes were then incubated in 1:1 mixture of 20% sucrose in PBS:OCT (Cryo
Optimal Cutting Temperature Compound, Sakura, Torrance, CA, USA) for 1 h, and flash frozen
in OCT. Cryosectioning was performed with a Leica CM1850 Cryostat, and serial retinal
sections of 14 µm thickness were mounted on Superfrost Plus slides (Fisher Scientific,
Pittsburgh, PA, USA). Retinal sections mounted on slides were washed with 1X PBSTx (1X
PBS with 0.1% TritonX-100), and incubated for 1 hr in blocking buffer (1X PBS with 5% goat
sera, 0.5% TritonX-100, 0.05% sodium azide). Retinal sections were incubated with primary
antibody for 2-3 hrs, followed by three 10 min washes with 1X PBSTx before incubation with
secondary antibody (Alexa Fluor-488 or Alexa-Fluor 568, Invitrogen, Carlesbad, CA, USA) for
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30 min. The nuclear marker, 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen, 1:5000 dilution)
was added for 10 min, and washed with 1X PBSTx before mounting with Prolong anti-fade
reagent (Invitrogen) and coverslipping. Slides were viewed and imaged on a laser scanning
confocal (Zeiss LSM 510) on a Zeiss LSM AxioImager Z1 microscope. Outer nuclear layer cell
quantification was conducted on retinal sections from 3 different animals with the highest ERG
responses in each treatment group. Serial sections for each retina were examined to determine
the area with greatest photoreceptor preservation, which typically showed a uniform preservation
in 40-50% of serial sections. Confocal images of DAPI stained nuclei were taken at five fixed
locations of a section, to control for variability across the eyecup. Confocal images were
analyzed using ImageJ software (NIH, Bethesda, MD) to determine the photoreceptor cell count,
which was reported as an average of the 15 measurements. Each measurement spanned
approximately 200 µm in width of the retina.
For retinal wholemounts, eyes were enucleated with the orientation maintained by
puncturing at the dorsal position, and fixed in 4% paraformaldehyde for 15 min. The anterior
segments were removed to create an eyecup, and a vertical incision was created at the most
dorsal position. The retina was carefully removed from the eyecup and fixed for an additional 612 hrs at 4°C. The retina was washed twice for 30 min prior to incubation in primary antibody
for 12-24 hrs at 4°C. Removal of excess primary antibody was conducted with two 30 min
washes, followed by incubation in secondary antibody for 12-24 hrs at 4°C, washed twice for 20
min, and mounted and coverslipped. Wholemounts were viewed and imaged on an Olympus
AX70 Provis microscope with an Optronics Microfire color CCD camera (Optronics, Golenta,
CA, USA), using Stereo Investigator (MBF Bioscience, Milliston, VT, USA) and PictureFrame
(Optronics, Golenta, CA, USA) software. Quantification of wholemounts was conducted using
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ImageJ software to analyze 20x objective wholemount images taken with the same exposure
time. Each data point, expressed in fluorescent arbitrary units, was an average of 9 measurements
obtained from 3 injected retinas with 3 images for each retina.
The following primary antibodies were used at the indicated dilutions: Human AIPL1
(1:1000) (Ramamurthy et al., 2004), PDE6αβγ (MOE) (1:2000) (CytoSignal Inc., Irvine, CA,
USA), PDE6β (1:1000) (Affinity BioReagents, Golden, CO, USA), cone PDEα’ (1:1000)
(Kirschman et al., 2010), rod opsin (4D2) (1:2000) (gift from Dr. Robert Molday, University of
British Columbia, Vancouver, British Columbia, Canada), red/green opsin (1:1000) (Chemicon,
Millipore, Billerica, MA, USA), PKCα (1:2000) (Thermo Fisher Scientific, Inc., Pittsburgh, PA,
USA). Rhodamine peanut agglutinin (PNA) (1:500) (Vector Laboratories, Inc., Burlingame, CA,
USA) and DAPI (1:5000) (4’,6-diamidino-2-phenylindole, Invitrogen) were also used in
immunocytochemistry.
Histologic, semithin sections, and transmission electron microscopy
For hematoxylin and eosin stained images, enucleated whole eyes were fixed in Alcoholic Z-fix
(Excalibur Pathology) for 48 hrs at room temperature. Serial sections of paraffin embedded fixed
whole eyes were mounted on slides (Excalibur Pathology). Images were collected on an
Olympus AX70 Provis microscope using PictureFrame software (Optronics, Golenta, CA, USA).
For light and transmission electron microscopy, enucleated eyes were lightly fixed in
freshly prepared fixative (2% paraformaldehyde, 2.5% glutaraldehyde, 0.1 M cacodylate buffer,
pH 7.5) for 30 min. The anterior segment and lens were removed and eye cups were returned to
fixative for 48 hours at room temperature, prior to dissection into 6-8 wedge-shaped pieces.
Wedges were dehydrated in a graded ethanol series, then embedded in Polybed 812
(PolySciences, Inc.,Warrington, PA, USA). Semi-thin (1 μm) sections were collected onto glass
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slides, stained with toluidine blue, and visualized using a Zeiss Axioimager 2 microscope
equipped with EC Plan-Neofluar 40x (N.A. 0.75) and 100x (1.3 N.A.) objectives to identify best
rescued areas. Thin sections (ca. 80 nm) from selected wedges were collected onto nickel grids,
stained with 2% uranyl acetate and lead citrate, and imaged using an FEI Morgagni transmission
electron microscope at 80 kV.
Statistical analyses
Statistical analyses were conducted on GraphPad Prism4 software (GraphPad Software, Inc., La
Jolla, CA, USA), using one-tailed unpaired t-tests for two group comparisons, and ANOVA
followed by Tukey-Kramer HSD post-hoc tests for multiple group comparisons.
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Results
Self-complementary AAV capsid mutant induces earlier and higher expression of hAIPL1
in retina
Self-complementary Y733F tyrosine capsid mutant AAV2/8 combines two recent
developments in AAV vectors shown to increase transduction efficiency and decrease expression
latency of reporter genes (Natkunarajah et al., 2008; Petersen-Jones et al., 2009; Kong et al.,
2010). To compare the onset and levels of expression of single-stranded AAV and selfcomplementary capsid mutant AAV, we injected ssAAV-RKp-hAipl1 (henceforth referred to as
ssAAV) or scAAV-Y733F-RKp-hAipl1 (henceforth referred to as scAAV) into postnatal day 14
(P14) wild-type retina. Viral titers were matched between ssAAV and scAAV for all experiments
throughout this study. The vectors expressed the human Aipl1 gene under the short rhodopsin
kinase promoter (RKp), which is active in both rod and cone photoreceptor cells as early as P2
(Young et al., 2003; Young et al., 2005; Khani et al., 2007). Expression of exogenously delivered
human AIPL1 was investigated through immunofluorescent staining of whole mounted injected
eyes with an antibody that specifically recognizes the human isoform of AIPL1. Eyes injected
with ssAAV exhibited low AIPL1 expression in sparse areas beginning at post-injection (pi) day
3, with progressive increases at pi day 5 and 7. Expression of AIPL1 began to plateau between pi
day 7 and 14 (Fig. 1A). In comparison, eyes injected with scAAV exhibited expression of AIPL1
in larger areas beginning at pi day 2 and uniformly high expression at pi day 3. Expression of
AIPL1 increased steadily and uniformly at pi day 5, 7, and 14 (Fig. 1A). Fluorescent counts
quantifying AIPL1 expression were conducted on three treated retina per post-injection time
point. Mean fluorescent counts were significantly higher in scAAV treated eyes than ssAAV
treated eyes at pi day 3, 5, and 14 (p < 0.0005) (Fig. 1B). scAAV treated retina had a four-fold
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higher mean fluorescent count than ssAAV at pi day 3, and a two-fold difference at pi day 5 and
pi day 14. Differences in AIPL1 expression were particularly evident at earlier time points, with
expression levels of scAAV at pi 3 greater than levels of ssAAV at pi 5.

Early administration of AAV-mediated gene replacement therapy efficiently rescues
photoreceptor function in Aipl1-/- mice
Aipl1-/- mice exhibit rapid and severe photoreceptor degeneration (Dyer et al., 2004;
Ramamurthy et al., 2004), with initiation of cell death at postnatal day 8 (P8) (Supplementary
Fig. 1). In addition, photoreceptor cells in these mice are not functional at any age tested
(Ramamurthy et al., 2004). Our goal was to compare the efficacy of ssAAV and scAAV in
preventing cell death and in rescuing visual function. Therefore, we injected AAV-hAipl1
subretinally into one eye of Aipl1-/- mice at postnatal day 2 (P2). At this early stage of retinal
development, rod photoreceptors in mice are beginning to form. Electroretinograms (ERGs), a
measure of light dependent electrical responses from photoreceptor cells and downstream
neurons, were conducted to evaluate photoreceptor function after treatment with either ssAAV or
scAAV. The a-wave in ERG correlates with photoreceptor activity, while the b-wave arises
mainly due to downstream bipolar cell activity. Representative ERG recordings at P30 under
dark-adapted (Fig. 2A) and light-adapted conditions (Fig. 2B), showed restoration of scotopic
and photopic ERG responses in ssAAV and scAAV treated eyes compared to a complete absence
of response in the contralateral untreated eye. The scAAV treated eye showed greater a- and bwave amplitudes and oscillatory potentials than the ssAAV treated eye at all dark-adapted
scotopic flash intensities of -3.6, -1.6, -0.6, and 0.4 log (cd · s/m2) flashes. At a flash intensity of
-0.6 log (cd · s/m2), the photoreceptor responses (a-wave amplitudes) of individual mice in each

44

treatment group showed intergroup variability (Fig. 2C). However, the mean group average for
scAAV was statistically higher than for ssAAV treated mice (p = 0.027; ssAAV treated mean =
49.5 ± 8.7 µV, n = 10; scAAV treated mean = 79.5 ± 11.6 µV, n = 10). This difference in group
means of a-wave amplitudes was statistically significant at every scotopic flash intensity
recorded (p values indicated in figure, ranging from p = 0.017 to p = 0.027) (Fig. 2D).

Early administration of AAV-mediated gene replacement therapy restores rod and cone
PDE6 expression and slows photoreceptor degeneration in Aipl1-/- mice
To evaluate the effects of Aipl1 replacement on photoreceptor survival, we examined the
retinal morphology in AAV treated and untreated control eyes. Immunocytochemical and
morphometric analyses were conducted at P65 after a single injection at P2. As expected, treated
eyes showed expression of hAIPL1 in photoreceptor inner segments and outer plexiform layer
(Kirschman et al., 2010; Sun et al., 2010) (Fig. 3A). Concomitant with the expression of hAIPL1,
rod and cone PDE6 was observed along with rod and cone opsins, indicating the presence of
intact rod and cone outer segments (Fig 3A). ssAAV treated eyes showed 4-5 rows of
photoreceptor cell nuclei compared to a complete loss of photoreceptors in the contralateral
untreated eye. scAAV treated retina had 5-6 rows of photoreceptor nuclei (Fig. 3A, and
Supplementary Fig. 2). To quantify the observed differences in outer nuclear layer thickness,
photoreceptor cell nuclei counts were conducted on retina from each treatment group. The mean
number of photoreceptor cell nuclei of scAAV treated retina was significantly greater than
ssAAV treated retina by 45% (p = 0.005; ssAAV mean = 125.92 ± 14.43; scAAV mean = 182.85
± 13.42) (Fig. 3B). In agreement with our ERG and morphology results, western blots showed
that retina from scAAV treated animals expressed higher levels of AIPL1 and rod PDE6 than
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ssAAV treated animals (Fig. 3C). This trend was also observed when protein levels were
examined at P35, where all scAAV treated animals expressed higher levels of AIPL1 and rod
PDE6 (Supplementary Fig. 3) at this earlier post-injection time point.

Early administration of AAV-mediated gene replacement therapy preserves photoreceptor
ultrastructure
The effectiveness of AAV-mediated gene replacement therapy on preserving
photoreceptor ultrastructure was evaluated through light and transmission electron microscopy.
Semi-thin sections showed scAAV treated retina with longer inner and outer segments compared
to ssAAV treated retina (Fig. 4A). At best, outer segments in ssAAV treated retina were 40-50%
of the length of outer segments in an age-matched wild-type retina, whereas scAAV treated
retina were 50-60% of wild-type retina (Fig 4A). Additionally, semi-thin sections showed similar
findings to immunohistochemical studies in outer nuclear layer thickness, with ssAAV treated
retina with 4-5 rows of nuclei and scAAV treated retina with 5-6 rows (Fig. 4A).
Ultrastructurally, both ssAAV and scAAV treated retina displayed intact photoreceptor outer
segments with normally organized and densely stacked disc membranes, similar to wild-type
retina (Fig. 4B).

Early administration of AAV-mediated gene replacement therapy restores visually guided
behavior in Aipl1-/- mice
To assess whether the observed rescue of electrophysiological responses and retinal
morphology result in improvements in visually guided behavior, P2 AAV treated mice were
tested with the Morris water maze at P60. The Morris water maze, adapted from Pang et al.
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(Pang et al., 2008), tested for the ability of the mice to visually locate an escape platform. Under
dim light conditions, untreated wild-type Aipl1+/+ mice took 3.45 ± 0.44 sec (n = 7) to locate
the platform (Fig. 5). In comparison, untreated Aipl1-/- mice located the platform in 24.09 ± 2.72
sec (n = 8), which was significantly greater than wild-type mice (p < 0.001). Aipl1-/- mice
treated with ssAAV found the platform in 6.88 ± 0.87 sec (n = 6), and scAAV treated mice took
7.82 ± 0.81 sec (n = 7), both of which were significantly less than untreated Aipl1-/- mice (p <
0.001). There was no statistical difference between ssAAV treated and wild-type mice, between
scAAV treated and wild-type mice, or between ssAAV and scAAV treated mice (p > 0.05 for all
comparisons, Analysis of Variance (ANOVA) with Tukey-Kramer Honestly Significant
Difference (HSD) statistical analysis).

Gene replacement therapy with self-complementary AAV capsid mutant effectively rescues
rod and cone function in Aipl1-/- mice with active photoreceptor degeneration
Our experiments comparing transduction kinetics of ssAAV and scAAV in wild-type
retina demonstrated higher expression of AIPL1 at earlier time points with scAAV treatment. We
hypothesized that this characteristic of scAAV is important in maximizing rescue of
photoreceptors during active degeneration in Aipl1-/- mice, since these mice have a rapid rate of
degeneration. To determine the efficiency of ssAAV and scAAV treatment in actively
degenerating retina, viral injections were administered at postnatal day 10 (P10). At this stage of
retinal development, photoreceptor cell death is evident in Aipl1-/- mice (Supplementary Fig. 1).
ERG recordings were conducted at P30 to examine the effects of the delayed ssAAV and scAAV
treatment on photoreceptor function. Representative ERG traces showed robust scotopic and
photopic responses elicited from scAAV treated animals compared to weak responses from
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ssAAV treated animals (Fig. 6A, B). The photoreceptor response (a-wave amplitudes) of
individual mice in each treatment group showed all scAAV treated animals with higher a-wave
amplitudes than ssAAV treated animals, and a significant difference in group means (p = 0.0006;
ssAAV treated mean = 4.22 ± 2.17 µV, n = 9; scAAV treated mean = 47.67 ± 10.73 µV, n = 9)
(Fig. 6C), under dark-adapted conditions with a flash intensity of -0.6 log (cd · s/m2).
Additionally, the difference in group means between ssAAV and scAAV treatment was
significant for a-wave and b-wave amplitudes recorded under dark-adapted conditions, at all
flash intensities of -3.6, -1.6, -0.6, and 0.4 log (cd · s/m2) (p values indicated in figure, ranging
from p = 0.003 to p = 0.00001) (Fig 6D, E). A similar trend was observed with light-adapted
ERG responses, a reflection of cone photoreceptor activity. A statistically significant difference
in average b-wave amplitudes elicited under light-adapted conditions with a 0.4 log (cd · s/m2)
flash intensity was observed (p = 0.014; ssAAV treated mean = 1.22 ± 1.22 µV, n = 9; scAAV
treated mean = 20.44 ± 7.86 µV, n = 9) (Fig. 6F), with robust cone responses in scAAV treated
animals. While ERG responses of ssAAV treated eyes were significantly lower than scAAV
treated eyes, they were significantly higher than contralateral untreated eyes at all flash
intensities (p < 0.05) (data not shown).

Gene replacement therapy with self-complementary AAV capsid mutant slows rod and
cone degeneration in Aipl1-/- mice with active photoreceptor degeneration
In P10 treated mice, the significant difference in ERG responses between ssAAV and
scAAV already observed at P30 led us to conduct behavioral assays and morphological analyses
at P35. Additionally, we wanted to accurately examine the behavioral and morphological
correlates of the low ERG responses elicited from ssAAV treated mice at P30. Morphological
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analyses were conducted to assess preservation of photoreceptors following delayed AAVmediated gene replacement in Aipl1-/- mice at P10. Retina from scAAV treated animals
maintained 5-6 rows of photoreceptor cell nuclei (Fig. 7A, and Supplementary Fig. 2). In
comparison, retina from ssAAV treated animals showed 2-3 rows of photoreceptor cell nuclei.
These findings were supported by our cell counting results demonstrating the presence of
significantly greater numbers of photoreceptor cell nuclei in retina from scAAV than ssAAV
treated animals (p = 0.0000001; ssAAV mean = 76.90 ± 11.99; scAAV mean = 275.50 ± 21.71)
(Fig. 7B).
Immunostaining for photoreceptor outer segment proteins such as rod and cone opsins
revealed sparse and short outer segments in retina from ssAAV treated animals, a pattern also
observed with immunostaining for rod and cone PDE6 (Fig. 7A). In contrast, retina from animals
treated with scAAV displayed denser and longer rod and cone outer segments (Fig. 7A).
Coincident with the presence of photoreceptor outer segments, retina from animals treated with
scAAV exhibited strong expression of AIPL1 in inner segments, and rod and cone PDE6 in
respective photoreceptor outer segments (Fig. 7A). Our immunofluorescence results are
supported by immunoblotting experiments demonstrating higher levels of hAIPL1 and rod PDE6
in the majority of retina from scAAV treated animals (lanes 6-10) compared to ssAAV treated
animals (lanes 1-5) (Fig. 7C). The amount of rod PDE6 in scAAV treated retina varied from 1040% of wild-type levels. In comparison, the amount of rod PDE6 in ssAAV treated retinas was
negligible, with 9% of wild-type rod PDE6 levels at best (lane 5).
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Gene replacement therapy with self-complementary AAV capsid mutant rescues visually
guided behavior in Aipl1-/- mice with active photoreceptor degeneration
To evaluate visually guided behavior following treatment at postnatal day 10 (P10), mice
were tested with the Morris water maze at P35 (Fig. 8). Similar to our previous results, Aipl1+/+
wild-type mice took 4.38 ± 0.45 sec (n = 6) to locate the escape platform, whereas Aipl1-/- mice
needed 25.20 ± 6.52 sec (n = 5) (p < 0.01). ssAAV treated mice took 24.00 ± 3.51 sec (n = 8),
which was significantly different from wild-type (p < 0.01), but not from Aipl1-/- mice (p >
0.05). These results indicate that the visually guided behavior in P10 ssAAV treated mice was
not improved from untreated Aipl1-/- mice. In contrast, the average time of scAAV treated mice
to find the platform was 6.69 ± 1.30 sec (n = 7), which was significantly less than ssAAV treated
mice and Aipl1-/- mice (p < 0.01), but not significantly different from Aipl1+/+ mice (p > 0.05),
indicating that treatment with scAAV at P10 restored visually dependent behavior to wild-type
levels. Similar results were observed when a comparison was conducted between ssAAV treated
mice demonstrating ERG responses and scAAV treated mice, where the average time of ssAAV
treated mice (n = 4, 17.87 ± 1.82 sec) was significantly different than scAAV treated mice (n = 7,
6.69 ± 1.30 sec) (p < 0.01), but not significantly different from Aipl1-/- mice (n = 5, 25.20 ±6.52
sec) (p > 0.05) (ANOVA with Tukey-Kramer HSD statistical analysis).
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Discussion
In this study, we demonstrated that the faster and greater transduction efficiency of scY733F-AAV2/8 over ssAAV2/8 led to greater preservation of visual function in AAV-mediated
gene replacement therapy of Aipl1 deficient mice, a model of severe Leber congenital amaurosis.
This is the first reported study to use sc-Y733F-AAV2/8 for rescue of vision in a model of rapid
retinal degeneration. Self-complementary AAV, shown to decrease expression latency and
increase transduction efficiency, is generally thought to have limited use due to the halved gene
packaging capacity of single-stranded AAV. However, it has been shown that efficient
packaging and expression of genes up to 3.3 kb may be possible (Wu, J. et al., 2007), extending
the utility of self complementary AAV. Additionally, the advent of capsid tyrosine mutations
provides a simple way to increase viral efficiency without placing additional size restrictions.
While mutations of surface-exposed tyrosine residues on viral capsids decrease ubiquitination
which largely improves transduction efficiency, the effect on expression latency remains unclear.
Interestingly, we observed differences between ssAAV and sc-Y733F-AAV (scAAV)
treatments in Aipl1-/- mice treated at P2, when photoreceptors are not yet fully developed and no
sign of degeneration is present. The aim of treating early was to provide maximal rescue of
photoreceptors. Despite early treatment, we observed consistently lower ERG responses and
photoreceptor cell survival in ssAAV treated compared to scAAV treated Aipl1-/- retina.
However, the magnitude of differences between the two treatment groups did not translate into a
difference in visually guided behavior under our lighting conditions. The observed differences
between the two treatment groups were likely due to the lower levels of AIPL1 expression
achieved with ssAAV, as demonstrated by our studies in wild-type retina. In contrast, the higher
AIPL1 expression with scAAV treatment provided greater ERG responses and photoreceptor
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survival. In addition to these benefits in preservation of photoreceptor structure and function,
viral vectors that achieve higher expression have a practical advantage, allowing for
administration of lower viral titers which is especially important in reducing potential adverse
effects. The use of the scAAV viral vector, therefore, may be warranted and beneficial in gene
replacement therapy clinical trials.
The functional advantage of scAAV was most striking following P10 administration,
when the Aipl1 deficient photoreceptors are undergoing active degeneration. Late treatment with
ssAAV achieved minimal photoreceptor cell survival and low ERG responses in a fraction of the
treated animals, with no evidence of vision guided behavior. In contrast, scAAV treated animals
showed greater photoreceptor cell survival, with concomitant ERG responses and vision guided
behavior. Following late scAAV treatment, ERG responses persisted until the last time point
tested at P60 (Supplementary Fig. 4). The preservation of vision achieved with both early and
late administration of scAAV treatment demonstrates stability of vision rescue. To summarize, in
a clinically relevant scenario of active photoreceptor degeneration, scAAV treatment showed
clear benefits over ssAAV in vision rescue.
The advantages in vision rescue with scAAV treatment were likely a result of the early
robust expression of hAIPL1 observed in our comparisons of transduction efficiency in wild-type
retina. It took an additional 3-4 days for expression levels of AIPL1 from ssAAV treatment to
reach a level attained by that of scAAV treatment. We speculate that the faster expression of
AIPL1 with scAAV translates into quicker restoration of functional PDE6 and stabilization of
cGMP levels, and subsequently greater preservation of outer segments. This proved particularly
critical in vision rescue in mice where photoreceptor degeneration has initiated. Additionally, the
higher expression achieved with scAAV contributed to the improved vision rescue. It is known
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that Aipl1 hypomorphic mice, which express 20-30% of wild-type AIPL1 levels, show abnormal
photoreceptor function and slow degeneration (Liu et al., 2004). In contrast, Aipl1 heterozygous
mice, with 50% of protein, show no signs of photoreceptor degeneration or dysfunction
(Ramamurthy et al., 2004). This indicates that a certain threshold level of AIPL1 is necessary for
normal photoreceptor function and survival. The lower expression of AIPL1 achieved with
ssAAV treatment in Aipl1-/- mice may lead to a number of photoreceptors that do not cross this
threshold, resulting in lower photoreceptor survival and subsequent lower ERG responses.
Higher AIPL1 expression levels achieved with scAAV treatment leads to a greater probability
that this threshold is surpassed in a larger number of photoreceptors, hence achieving greater
photoreceptor survival and restoration of vision.
The demonstrated functional advantages of second generation AAV vectors, such as scY733F-AAV2/8, are important in the future progress of AAV-mediated gene replacement
therapy clinical trials. There is an impetus to broaden gene therapy clinical trials to treat a wider
severity spectrum of inherited retinal dystrophies. Recent clinical studies report cases of
adolescent and adult patients with genetic defects associated with rapid retinal degeneration, who
show varying extents of ONL preservation and inner and outer segment integrity as observed
with optical coherence tomography (OCT). This has been observed in patients with defects in
CEP290 (Cideciyan et al., 2007; Pasadhika et al., 2010), GUCY2D (Pasadhika et al., 2010),
RPGRIP1 (Jacobson et al., 2007), and AIPL1 (Jacobson et al., 2011; Testa et al., 2011). These
studies show that patients with genetic defects associated with rapid retinal degeneration may
potentially benefit from AAV-mediated gene replacement therapy. The improved transduction
onset and efficiency of second generation AAV vectors, such as sc-Y733F-AAV2/8, provides a
larger therapeutic range for treating a spectrum of genetic defects with varying rates of disease
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progression. Additionally, the longevity of such residual photoreceptors cannot be predicted for
each patient, and the best practical option is to provide the most rapid acting and efficient
treatment possible. It remains to be examined whether infants and young children afflicted with
LCA have a substantial amount of photoreceptors that can be salvaged with early gene therapy
treatment. The aim of gene therapy here would be prevention of massive loss of retinal neurons.
Our results demonstrated that sc-Y733F-AAV2/8 also provided functional benefits over
ssAAV2/8 in early treatment of rapid retinal degeneration. Additional concurrent progress in
viral-mediated gene delivery and clinical characterization is necessary to advance into clinical
trials, but emerging evidence in both areas show promising prospects for gene replacement
therapy to successfully treat a wider spectrum of genetic defects and severities of retinal
dystrophies.
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Figures
Fig. 1

Fig. 1. scAAV provides earlier onset and higher expression compared to ssAAV following
subretinal injection into wild-type retina. (A) Wholemount images from injected retina at
indicated post-injection (pi) times. All images were taken with the same exposure time at x20
magnification. Scale bar, 100 µm. (B) Quantitative analysis of AIPL1 expression in wholemount
images, expressed in arbitrary units of fluorescence (AU). Except for pi 7, statistically significant
differences in units of fluorescence between ssAAV and scAAV were observed. Error bars,
±SEM.
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Fig. 2

Fig. 2. Light-dependent photoreceptor responses from Aipl1-/- mice following early AAV
treatment. One eye of Aipl1-/- mice was injected at P02 with the indicated AAV and ERGs
were recorded at P30. ERG responses from (A) dark- and (B) light-adapted conditions were
measured at the indicated log (cd · s/m2) flash intensities. Traces from a contralateral untreated
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eye and an age-matched wild-type mouse are shown for comparison. (C) Dark-adapted
photoresponses from Aipl1-/- treated mice at the flash intensity of -0.6 (log cd · s/m2). Each data
point represents the measured a-wave amplitude of an individual treated mouse. The group
average of scAAV treated mice was significantly higher than the group average of ssAAV
treated mice (p ≤ 0.027). (D) Comparison of mean rod photoreceptor response (a-wave
amplitude) between ss and scAAV treatments over increasing flash intensities. Average a-wave
amplitudes from the scAAV treated mice were significantly greater than the ssAAV treated mice
at all intensities (p ≤ 0.027). Error bars, ±SEM.
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Fig. 3

Fig. 3. Restoration of photoreceptor morphology and PDE6 expression in Aipl1-/- retina
following early AAV treatment. Aipl1-/- mice were treated at P2 and retinas were collected at
P60 for immunocytochemistry and immunoblots. (A) Confocal images of retinal sections stained
with indicated antibodies. Peanut agglutinin (PNA) (red) which stains the cone sheath is a cone
marker. Cell nuclei were stained with DAPI (blue). Images were taken at x63 magnification.
Scale bar, 20 µm. OS, outer segment; IS, inner segment; ONL, outer nuclear layer; INL, inner
nuclear layer. (B) Photoreceptor cell nuclei quantification of ssAAV and scAAV treated retina
using retinal sections stained with DAPI. scAAV treatment showed significantly higher ONL
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cell counts than ssAAV treated retina (p ≤ 0.005). Error bars, ±SEM. (C) Western blots of retinal
extracts from ssAAV and scAAV treated animals with indicated antibodies. Untreated Aipl1-/(lane 5), wild-type (lane 6), and transgenic hAipl1 (lane 7) retina served as controls. PKCα
expressed in bipolar cells, is a loading control.
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Fig. 4

Fig. 4. Restoration of photoreceptor ultrastructure following early AAV treatment. (A)
Semithin light micrographs of P35 Aipl1-/- retina following treatment at P2 with ssAAV or
scAAV. Semithin sections from a P35 Aipl1+/+ retina are shown for comparison. Scale bar, 20
µm. RPE, retinal pigmented epithelium; OS, outer segment; IS, inner segment; ONL, outer
nuclear layer. (B) Electron micrographs at x2200 (top panel) and x8900 (bottom panel)
magnification. RPE, retinal pigmented epithelium; MV, microvilli; OS, outer segment; IS, inner
segment. Scale bars, 5 µm (top panel) and 1 µm (bottom panel).
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Fig. 5

Fig. 5. Vision-dependent behavior is restored in Aipl1-/- mice following early ss- or sc-AAV
treatment. Mice received treatment at P2 and were tested at P60 with the Morris water maze.
Age-matched untreated Aipl1-/- and Aipl1+/+ groups served as controls. The time to reach the
escape platform was recorded and reported as group averages. Treatment with both AAVs
restored vision-dependent behavior to wild-type Aipl1+/+ levels (p > 0.05), which were
significantly different from untreated Aipl1-/- mice (**p < 0.001, ANOVA with Tukey-Kramer
HSD post-hoc test). Error bars, ±SEM.
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Fig. 6

Fig. 6. Light-dependent photoresponses in Aipl1-/- mice following late administration of
AAV-mediated gene replacement therapy. ERG responses were recorded at P30, following
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injection at P10. ERG tracings were recorded under (A) dark-adapted and (B) light-adapted
conditions at the indicated flash intensities. (C) A-wave amplitudes of individual mice in ssAAV
and scAAV treated groups, derived from ERG recordings at -0.6 (log cd · s/m2) flash intensity.
All scAAV treated eyes showed higher a-wave amplitudes than ssAAV treated eyes.
Additionally, the group average of scAAV treated mice was significantly higher than the group
average of ssAAV treated mice (p ≤ 0.0006). Quantitative analysis of mean (D) a-wave and (E)
b-wave amplitudes showed significantly higher amplitudes in the scAAV treated group than the
ssAAV treated group across all flash intensities under dark-adapted conditions (p ≤ 0.003). (F)
Quantitative analysis of mean b-wave amplitudes from ERGs recorded under light-adapted
conditions. Higher photopic responses were elicited from scAAV treated eyes compared to
ssAAV treated eyes (p ≤ 0.014). Error bars, ±SEM.
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Fig. 7

Fig. 7. Photoreceptor morphology of Aipl1-/- retina following late administration of AAVmediated gene replacement. Aipl1-/- mice were treated at P10 and retinas were collected at P35
for immunocytochemistry. (A) Confocal images of retinal sections stained with indicated
antibodies. Peanut agglutinin (PNA) (red) is used as a cone marker. Cell nuclei are stained with
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DAPI (blue). Images were taken at x63 magnification. Scale bar, 20 µm. OS, outer segment; IS,
inner segment; ONL, outer nuclear layer; INL, inner nuclear layer. (B) Quantification of
photoreceptor cell nuclei showed significantly greater nuclei in scAAV compared to ssAAV
treated retina (p ≤ 0.0000001). Error bars, ±SEM. (C) Western blots of ssAAV (lanes 1-5) and
scAAV (lanes 6-10) treated retina. Untreated Aipl1-/- (lane 11), wild-type (lane 12), and
transgenic hAipl1 (lane 13) retina serve as controls. PKCα expressed in bipolar cells, is a loading
control.
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Fig. 8

Fig. 8. Vision-dependent behavior is restored to Aipl1-/- mice exclusively by scAAV
treatment. Mice were tested at P35 after AAV administration at P10 with the Morris water maze
assay. The mean time of scAAV treated mice was similar to wild-type Aipl1+/+ mice (p > 0.05),
and both were significantly lower than untreated Aipl1-/- and ssAAV treated mice (*p < 0.01 at
group indicated comparisons, ANOVA with Tukey HSD). The mean time of ssAAV treated
mice was not significantly different from untreated Aipl1-/- mice (p > 0.05). Error bars, ±SEM.
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Supplementary Fig. 1

Supplementary Fig. 1. Rate of retinal degeneration and vision loss in the Aipl1-/- mouse.
(A) Immunostaining of Aipl1+/+ and Aipl1-/- retina at postnatal day 2 (P2), P8, P10, and P35
with propidium iodide, a marker of cell death. Arrowheads indicate photoreceptor cell death in
Aipl1-/- retina, which began at P8 and was clearly evident at P10. Images were taken at x40
magnification. Scale bar, 20 µm. ONL, outer nuclear layer; INL, inner nuclear layer.
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Supplementary Fig. 2

Supplementary Fig. 2. Photoreceptor rescue spanned the retina following both early and
late administration of scAAV. Hematoxylin and eosin (H&E) sections of Aipl1-/- retina at P35
following scAAV treatment at (A) P2, and (B) P10. An untreated contralateral eye is shown for
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comparison. Images of the eyecup were taken at x10 and photomerged, and at x40 magnification
for inset images. Scale bar, 20 µm.
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Supplementary Fig. 3

Supplementary Fig. 3. Protein expression at P35 following early administration of ssAAV
and scAAV. Western blots of retina from Aipl1-/- mice at P35 following treatment at P2, probed
with the indicated antibodies. Representative samples from three ssAAV (lanes 1-3) and scAAV
(lanes 4-6) treated mice are shown. Untreated Aipl1-/- (lane 7), wild-type (lane 8), and transgenic
hAipl1 (lane 9) served as controls. PKCα expressed in bipolar cells, is a loading control.
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Supplementary Fig. 4

Supplementary Fig. 4. Longitudinal ERG responses recorded from a P10 treated scAAV
mouse. ERG recordings from a representative individual mouse at (A) P30 and (B) P60 show
maintenance of dark-adapted and light-adapted photoresponses, achieved with late
administration of scAAV treatment. Dark-adapted ERG responses were elicited with the
indicated flash intensities of -3.6, -1.6, -0.6, and 0.4 log (cd · s/m2). Light-adapted ERG
responses were elicited with a flash intensity of 0.4 log (cd · s/m2).
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Chapter 3
P351Δ12 Aipl1 mutation: a model of cone-rod dystrophy
Abstract
Defects in aryl hydrocarbon receptor interacting protein-like1 (Aipl1) are typically
associated with the most severe of inherited retinal degenerations, Leber congenital amaurosis
(LCA). Pre-clinical rescue studies of Aipl1-null mice, a model for LCA that has the most rapid
retinal degeneration of any mouse model, have mainly served as proof-of-principle to
demonstrate that even the most severe of retinal dystrophies can be rescued. However, reports of
Aipl1 defects associated with less severe IRDs, such as retinitis pigmentosa (RP) and cone-rod
dystrophy (CORD), highlight the potential for Aipl1 to be a candidate gene for future AAVmediated gene therapy clinical trials. Specifically, the P351Δ12 hAipl1 mutation, a defect in the
C-terminal primate-specific ‘hinge’ region of AIPL1, has been linked to autosomal dominant
CORD and juvenile RP. Autosomal dominant retinal degeneration has not been otherwise
associated with Aipl1, and is important to evaluate since it indicates that AAV-mediated gene
replacement may not be helpful despite the slower degeneration associated with CORD and RP.
Other mutations have also been reported in the AIPL1 hinge region, although the function of this
primate-specific region remains unknown.
We sought to examine the effects of the P351Δ12 hAipl1 mutation by generating a
transgenic mouse with this mutation. As compared to a transgenic line expressing wildtype
hAipl1 under the same mCrx promoter construct, mutant P351Δ12 hAipl1 mice demonstrated a
CORD phenotype with early defects in cone-mediated vision and subsequent degeneration. The
mCrx promoter is active in both rods and cones as early as embryonic day 12.5 (E12.5). A
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dominant phenotype was observed in double transgenic animals expressing both mutant
P351Δ12 hAIPL1 and WT hAIPL1, in agreement with the autosomal dominant inheritance
observed in patients with the P351Δ12 hAipl1 mutation. Interestingly, we were able to rescue
cone-mediated vision in P351Δ12 hAipl1 mice following AAV-mediated gene delivery of WT
hAipl1 despite the dominant phenotype of the P351Δ12 mutation. Our transgenic P351Δ12
hAipl1 mouse offers a novel model of Aipl1-CORD, with distinct defects from both the Aipl1null mouse mimicking LCA and the Aipl1-hypomorphic mice mimicking a slow progressing RP.
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Introduction
Inherited retinal degeneration (IRD) is a group of blinding disorders affecting
approximately 1 in 3000 people (Daiger et al., 2007). Multiple forms of inherited retinal
degenerations exist with varied onset, symptoms, severity, and progression of disease. Leber
congenital amaurosis (LCA) shows the earliest onset and greatest severity of inherited retinal
dystrophies, presenting in early infancy with severe visual impairment and absent or markedly
reduced rod and cone-mediated electroretinograms (ERG). Other IRDs such as retinitis
pigmentosa (RP) and cone-rod dystrophy (CORD) show a greater variability in onset and rate of
disease progression. Additionally, while LCA patients show severe defects early on in both rodand cone-mediated vision, RP patients present with night blindness as the first visual impairment
alongside normal visual acuity. In contrast, CORD patients initially present with decreased visual
acuity, central vision loss, and dyschromatopsia, with progressive loss in peripheral, rodmediated vision. Successful clinical trials of gene replacement therapy improving visual function
in LCA patients with defects in retinal pigmented epithelium-specific 65 kDa protein (Rpe65)
has garnered attention to finding another candidate gene for treatment. Outside of the unusual
circumstance of Rpe65-LCA, where patients show significant visual defects disproportionate to
slow photoreceptor loss (Jacobson et al., 2005; Cideciyan 2010), the slower disease progression
of CORD and RP may indicate a larger therapeutic window in patients.
One such candidate gene for future AAV-mediated gene replacement is aryl hydrocarbon
receptor interacting protein-like 1 (Aipl1). Although defects in Aipl1 are mainly associated with
autosomal recessive LCA, sporadic reports have linked Aipl1 to less severe IRDs of CORD,
juvenile RP, non-early onset RP, and later onset retinal degeneration (Sohocki et al., 2000b;
Vallespin et al., 2007; Walia et al., 2010; Jacobson et al., 2011). These cases point to a subset of
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Aipl1 patients who may be better candidates for gene replacement therapy due to a slower
disease progression. Several non-LCA Aipl1 cases are linked to defects in the C-terminal
primate-specific proline-rich region of Aipl1 (Fig. 1A, grey box), specifically mutations P351∆12
(cDNA del1053-1064) and A336∆2 (cDNA del1008-1009) (Sohocki et al., 2000a; Sohocki et al.,
2000b). P351Δ12 hAipl1 has been associated with autosomal dominant CORD and juvenile RP.
Autosomal dominant disease has not been otherwise reported with Aipl1, and is important to
examine because it indicates a dominant negative mechanism of dysfunction differing from the
loss of function observed with truncation mutation W278X. Autosomal dominance is also
clinically important to examine as it potentially indicates that AAV-mediated gene replacement
would not be helpful for the P351Δ12 hAipl1 mutation, despite a slower disease progression.
Lastly, it may shed light on the function of the C-terminal primate-specific proline-rich hinge
region of human Aipl1. The function of the hinge region in hAipl1 remains unknown, although
the additional size provided by this 56 aa region has been advantageously used to differentiate
mouse and exogenously introduced human Aipl1 in transgenic and AAV-mediated rescue studies
(Tan et al., 2009; Kirschman et al., 2010; Sun et al., 2010).
The aim of this study was to examine the effects of the patient mutation, P351Δ12
hAipl1. We sought to characterize the visual dysfunction associated with this mutation, to
evaluate whether this mutation leads to retinal degeneration in a dominant fashion, and to
attempt to rescue the visual dysfunction with AAV-mediated gene replacement. To do so, we
generated transgenic mice expressing this hinge region mutation alongside control mice
expressing wildtype hAipl1, both expressed under the mouse Crx (cone-rod homeobox)
promoter.
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Materials and Methods
Animals
All experiments involving animals described in this stdy were approved by the Institutional
Animal Care and Use Committee at West Virginia University (WVU). Mice were maintained
under 12-h light / 12-h dark light cycles with food and water provided ad libitum.
Generation of transgenic hAipl1 mice
Full length hAipl1 was amplified from a human retinal cDNA library and engineered by
polymerase chain reactions (PCR) with an N-terminal Flag epitope tag and cloned under the 2.3
kb mCrx promoter (Furukawa et al., 2002) using a mCrx-LacZ vector generously provided by
Dr. Takahisa Furukawa (Osaka Bioscience Institute, Osaka, Japan). The P351Δ12 hAipl1
mutation was introduced through amplification with reverse primer 5’
CAGCTCTGCAGATGGTGCTGTGGGTGGCTCTGTGGATGACTGTGC 3’, introducing a 12
bp deletion at nucleotide position 1053-1064, and also cloned under the mCrx promoter. All PCR
reactions were performed with Phusion GC DNA polymerase master mix (Finnymes, Thermo
Scientific, Lafayette, CO, USA), following manufacturer instructions for cycling conditions and
the sequence verified using Big Dye Terminator ready reaction kit (Perkin Elmer, Waltham, MA,
USA). mCrx-hAipl1 (wildtype) and mCrx-P351Δ12 hAipl1 (mutant) was digested, purified using
the Wizard SV Gel and PCR Clean-Up system (Promega, Madison, WI, USA), and injected into
the pronuclei of oocytes from superovulated FVB/N females (WVU Transgenic Animal Core
Facilities) followed by implantation into pseudopregnant females. Wildtype- and mutant
P351Δ12 hAipl1 transgenic founders were identified through PCR primers amplifying an 750 bp
fragment spanning the 3’ region of the mCrx promoter and 5’ region of hAipl1, using forward
primer 5’ CTGGTTGCAGGCAAGAGT 3’ and reverse primer 5’
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GTCCGCTCCTCATCACATTT 3’. Founders were backcrossed into wildtype 129sv mice to
overcome the Pde6brd1 mutation present in the FVB strain, and further backcrossed with Aipl1
knockout mice in a mixed C57Bl/129sv background described previously (Ramamurthy et al.,
2004; Ku et al., 2011).
Electroretinographic (ERG) analysis
Mice were dark-adapted overnight prior to testing. Eyes were topically dilated with a 1:1 mixture
of tropicamide: phenylephrine hydrochloride. For ERG testing, mice were placed on a heated
platform with continuous flow of isoflurane anesthesia through a nose cone (1.5% isoflurane
with 2.5 liters per minute (lpm) oxygen flow rate). A reference electrode was placed
subcutaneously in the scalp. ERG responses were recorded from both eyes with silver wire
electrodes placed on each cornea, with contact being made with a drop of hypromellose solution
(2% hypromellose in PBS) (Gonioscopic Prism Solution, Wilson Ophthalmic, Mustang, OK,
USA). Rod dominated responses were elicited in the dark with flashes of LED white light at
increasing flash intensities. Light-adapted cone responses were elicited with white light flashes
in the presence of a 30 cd/m2 rod-desensitizing white background light. ERGs were performed on
the UTAS Visual Diagnostic System with BigShot Ganzfeld with UBA-4200 amplifier and
interface, and EMWIN 9.0.0 software (LKC Technologies, Gaithersburg, MD, USA).
Optokinetic responses (OKR)
Analysis of mouse optokinetic responses were examined using the OptoMotry system
(CerebralMechanics, Inc., Lethbridge, Alberta, Canada). Briefly, the system consists of a square
array of four computer monitors and an elevated platform on which a freely moving mouse is
placed. The mouse is observed from above through a camera mounted at the top. The system was
also adapted for measuring optokinetic responses at scotopic light levels, by surrounding the
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platform with a large cyclinder of neutral density filters (E-Colour #211 0.9 ND, Rosco
Laboratories, Inc., Glendale, CA, USA), and observing the mouse using NightVision camera
mode (Sony, San Diego, CA, USA) under a circular array of 6 infrared lights (OSRAM Opto
Semiconductors, Inc., Sunnyvale, CA, USA), as described previously (Kolesnikov et al., 2010).
The computer monitors form a virtual cylinder of rotating sine-wave vertical gratings which
randomly rotates clockwise or counterclockwise as controlled by the OptoMotry computer
program. Mice reflexively respond to the rotating gratings by turning their head in the
corresponding direction of the grating. The observer registers the mouse behavior through the
two-alternative forced-choice protocol (Umino et al., 2006), picking either clockwise or
counterclockwise, and the computer program changes the grating spatial frequency (in the visual
acuity mode) using the random staircase paradigm, until the threshold is reached at 70% of the
trials (Umino et al., 2008). Visual acuity was defined as the threshold for spatial frequency of
gratings and measured at the optimal speed (Sp) of 12.0 deg/s (Umino et al., 2008). In this mode,
spatial frequency (Fs) was randomly changed by the computer protocol, starting from 0.042
cyc/deg, until threshold or maximal spatial frequency was determined. Temporal frequency (Ft)
was automatically adjusted by the computer program based on the equation, Ft = Sp x Fs. Lastly,
the OptoMotry apparatus can measure threshold spatial frequency from each eye independently,
in a freely moving mouse without any suturing (Douglas et al., 2005). This is because the
optokinetic tracking response is elicited when motion is in the temporal-to-nasal direction of the
visual field. Thus, counterclockwise grating rotation will drive tracking through the right eye and
elicit a counterclockwise optokinetic response; whereas clockwise grating rotation drives
tracking through the left eye. This property of the apparatus was taken advantage of to
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independently measure treated and untreated eyes in mice receiving AAV-mediated gene
delivery.
Immunoblotting, immunohistology, and morphometric analysis
Mice were euthanized by CO2 inhalation and eyes were enucleated. For immunoblots, flash
frozen retinal samples dissected from enucleated eyes were sonicated in phosphate buffered
saline (PBS,137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4·7H2O, 1.4 mM KH2PO4, with
protease inhibitors and 10 mg/ml dithiothreitol (DTT)). Protein concentrations were measured
using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA). 150
µg total protein samples were resolved on a 8.7 cm long 10% polyacrylamide SDS-PAGE
resolving gel (Criterion Midi format, Bio-Rad, Hercules, CA, USA), or on a longer format 16 cm
long 9% polyacrylamide SDS-PAGE resolving gel where specified (Hoefer, Inc., San Francisco,
CA, USA), and transferred onto polyvinylidene difluoride membranes (Immunobilon-FL,
Millipore, Billerica, MA, USA). Membranes were blocked with blocking buffer (Rockland Inc.,
Gilbertsville, PA, USA) for 30 min at room temperature, and incubated with the indicated
primary antibodies. Blots were washed in PBST (PBS with 0.1% Tween-20) twice for 20 min
and incubated in secondary antibody, goat anti-rabbit or goat anti-mouse IRDye 680 (LI-COR
Biosciences, Lincoln, NE, USA) for 30 min at room temperature. After 3 washes with PBST,
membranes were scanned using the Odyssey Infrared Imaging System (LI-COR Biosciences,
Lincoln, NE, USA), and bands quantified using Odyssey Infrared Imaging System software.
For immunohistochemical studies, eyes were immersed in 4% paraformaldehyde fixative
for 15 min prior to removal of the anterior segments and lens. Eyecups were fixed for an
additional 2 h, washed in PBS for 20 min, incubated in 10% sucrose/PBS for 1 h at room
temperature, and transferred to 20% sucrose/PBS for overnight incubation at 4°C. Eyes were
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then incubated in 1:1 mixture of 20% sucrose in PBS:OCT (Cryo Optimal Cutting Temperature
Compound, Sakura, Torrance, CA, USA) for 1 h, and flash frozen in OCT. Cryosectioning was
performed with a Leica CM1850 Cryostat, and serial retinal sections of 14 µm thickness were
mounted on Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA, USA). Retinal sections
mounted on slides were washed with PBSTx (PBS with 0.1% TritonX-100), and incubated for 1
hr in blocking buffer (PBS with 5% goat sera, 0.5% TritonX-100, 0.05% sodium azide). Retinal
sections were incubated with primary antibody for 2-3 hrs, followed by three 10 min washes with
PBSTx before incubation with secondary antibody (Alexa Fluor-488 or Alexa-Fluor 568,
Invitrogen, Carlesbad, CA, USA) for 30 min. The nuclear marker, 4’,6-diamidino-2phenylindole (DAPI, Invitrogen, 1:5000 dilution) was added for 10 min, and washed with
PBSTx before mounting with Prolong anti-fade reagent (Invitrogen) and coverslipping. Slides
were viewed and imaged on a laser scanning confocal (Zeiss LSM 510) on a Zeiss LSM
AxioImager Z1 microscope.
The following primary antibodies were used at the indicated dilutions: Human AIPL1
(1:2500) (Ramamurthy et al., 2004), human and mouse AIPL1 (1:2500) (gift from Dr. Tiansen
Li, National Eye Institute, Bethesda, MD), PDE6αβγ (MOE) (1:2000) (CytoSignal Inc., Irvine,
CA, USA), PDE6β (1:1000) (Affinity BioReagents, Golden, CO, USA), cone PDEα’ (1:1000)
(Kirschman et al., 2010), mouse cone arrestin (1:1000) (gift from Dr. Wolfgang Baehr,
University of Utah, Salt Lake City, UT), guanylyl cyclase-E (GC-E) (gift from Dr. Baehr),
red/green opsin (1:1000) (Chemicon, Millipore, Billerica, MA, USA). Rhodamine peanut
agglutinin (PNA) (1:500) (Vector Laboratories, Inc., Burlingame, CA, USA) and DAPI (1:5000)
(4’,6-diamidino-2-phenylindole, Invitrogen, Grand Island, NY, USA) were also used in
immunocytochemistry.
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Histologic, semithin sections, and transmission electron microscopy
For light and transmission electron microscopy, mice underwent transcardial fixation perfusion
(Tissue Processing and Analysis Core, WVU) prior to retinal sample collection. Briefly, mice
were deeply anesthetized with ketamine/xylazine (100 mg/kg ketamine, 10 mg/kg xylazine) prior
to perfusion. The animal was perfused through the ascending aorta with a cannula attached to a
perfusion pump (Harvard Apparatus, Holliston, MA, USA) with a pressure-relieving incision
made in the right atrium. A vascular rinse was conducted prior to perfusion fixation (1%
paraformaldehyde, 1.25% glutaraldehyde, 0.1 M sodium cacodylate buffer, pH 7.5). Enucleated
eyes were further fixed (2% paraformaldehyde, 2.5% glutaraldehyde, 0.1 M cacodylate buffer,
pH 7.5) for 30 min prior to dissection and removal of the anterior segment and lens, and
extensively fixed for 48 hours at room temperature. The fixed eyecup was dissected into 6-8
wedge-shaped pieces. Wedges were dehydrated in a graded ethanol series, then embedded in
Polybed 812 (PolySciences, Inc., Warrington, PA, USA). Semi-thin (1 μm) sections were
collected onto glass slides, stained with toluidine blue, and visualized using a Zeiss Axioimager
2 microscope equipped with EC Plan-Neofluar 40x (N.A. 0.75) and 100x (1.3 N.A.) objectives to
identify best rescued areas. Thin sections (ca. 80 nm) from selected wedges were collected onto
nickel grids, stained with 2% uranyl acetate and lead citrate, and imaged using an FEI Morgagni
transmission electron microscope at 80 kV.
Generation of recombinant AAV vectors
Full-length human Aipl1 was amplified from pAAV-RKp-hAipl1 plasmid (Sun et al., 2010) with
primers that engineered flanking Kpn-I and Eag-I sites, and cloned into the scAAV packaging
vector (University of Florida, Retinal Gene Therapy Group), to generate the sc-RKp-hAipl1
plasmid. All PCR amplifications were performed with Phusion GC DNA polymerase master mix
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(Finnymes, Thermo Scientific, Lafayette, CO, USA), following manufacturer instructions for
cycling conditions. All plasmids were sequenced with the Big Dye Terminator ready reaction kit
(Perkin Elmer, Waltham, MA, USA). The sc-RKp-hAipl1 plasmid was used to produce the selfcomplementary AAV8 Y733F surface-exposed tyrosine residue capsid mutant (scAAV2/8Y733F-RKp-hAipl1) viral vector described previously (Ku et al., 2011) with a viral titer of 1.2 x
1013 viral particles per mL.
Subretinal injection
Transgenic mice injected at postnatal day 10 (P10) and P15 were placed under general anesthesia
with an intraperitoneal injection of ketamine (90 mg kg-1) / xylazine (9 mg kg-1) and received a
drop of topical anesthetic, proparacaine hydrochloride (0.5%, Akorn, Lake Forest, IL, USA),
followed by a drop of dilation solution, consisting of a 1:1 mixture of tropicamide (1%, Alcon,
Fort Worth, TX, USA) : phenylephrine hydrochloride (2.5%, Bausch and Lomb, Tampa, FL,
USA). For injection into mice prior to eyelid opening, an incision was made along the natural
future eyelid line with surgical vannas scissors. A small incision was then made in the sclera just
outside the pupillary margin with a 36-gauge needle. Viral solution was injected into the
subretinal space using a pulled glass pipette attached to a pneumatic injector (MINJ-PD, Tritech
Research, Los Angeles, CA, USA) through a transcorneal approach (Matsuda and Cepko 2004).
Each animal received 1.25 µl of AAV in the right eye, and no injection in the untreated
contralateral eye. Visualization during injection was aided by the addition of 0.1% fluorescein
(100 mg ml-1 AK-FLUOR, Alcon, Fort Worth, TX, USA) to the viral solutions.
Statistical analyses
Statistical analyses were conducted on GraphPad Prism6 software (GraphPad Software, Inc., La
Jolla, CA, USA), using two-tailed unpaired t-tests for two group comparisons, and ANOVA with

83

Bonferronni correction for multiple group comparisons.
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Results
Generation of wildtype- and mutant P351Δ12 hAipl1 mice
To examine the effects of the P351Δ12 hAipl1 mutation, a 12 bp, 4 aa in-frame deletion
in the C-terminal proline-rich region of hAIPL1 (Fig. 1A), transgenic P351Δ12 hAipl1 mice were
generated. A control transgenic line expressing wildtype hAipl1 (designated WT hAipl1) was
generated alongside the transgenic mutant line. Both wildtype and mutant transgenes were driven
by the 2.3 kb mCrx promoter (Fig. 1B), active beginning at embryonic day 12.5 (E12.5) in retinal
progenitor cells (Furukawa et al., 2002). We chose the mCrx promoter due to its early activity
and because it drives expression in both rod and cone photoreceptors (Furukawa et al., 2002), an
important property since cone cell death occurs in the absence of Aipl1 in a previous transgenic
model expressing hAipl1 (Kirschman et al., 2010) driven by Nrl (neural retina-specific leucine
zipper) (pNrl-hAipl1), a known rod-specific promoter (Akimoto et al., 2006; Kirschman et al.,
2010; Kautzmann et al., 2011). Transgenic WT hAipl1 mice were backcrossed into mouse Aipl1null mice to generate WT hAipl1 (mAipl1+/-) (designated as WT hAipl1 (+/-)) and WT hAipl1
(mAipl1-/-) (designated as WT hAipl1 (-/-)) littermates. The same breeding scheme was
conducted with the experimental P351Δ12 hAipl1 transgenic mice. Mice from both lines were
normal, healthy, and fertile, with no gross morphological abnormalities. All comparisons
subsequently made are between control WT hAipl1 and experimental P351Δ12 hAipl1 in a
mAipl1-null background (WT hAipl1 (mAipl1-/-) and P351Δ12 hAipl1 (mAipl1-/-)) unless
otherwise explicitly stated.
Protein expression of P351Δ12 hAIPL1 was comparable to WT hAIPL1 (Fig. 2). To note,
the mobility of mutant P351Δ12 hAIPL1 was shifted, running slightly below WT hAIPL1 in
immunoblots. Additionally, with the flag-epitope tag, both WT and P351Δ12 hAipl1 run slightly
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higher than non-tagged hAipl1. Expression of wildtype and mutant hAIPL1 is greater than 50%
of endogenous mAIPL1 levels, as quantified through the use of an AIPL1 antibody that
recognizes human and mouse AIPL1 equally (gift from Dr. Tiansen Li). This is equivalent to
mAipl1 heterozygous mice (mAipl1+/-) which show no visual dysfunction or retinal degeneration
(Ramamurthy et al., 2004).

P351Δ12 hAipl1 mice show drastically reduced photopic responses and reduced scotopic
responses at an early age
Electroretinography (ERG) was performed at P15, shortly after eyelid opening in mice, to
evaluate whether the P351Δ12 hAipl1 mutation leads to visual deficits. P351Δ12 hAipl1 (mAipl1/-

) mice had markedly reduced photopic, cone-mediated ERG responses, of approximately 40%

of ERG responses from WT hAipl1 (mAipl1-/-) mice (p < 0.0005 at all light intensity
comparisons; log 0.4 WT hAIPL1 mean = 73.20 ± 6.96 µV, n=5; log 0.4 P351Δ12 hAIPL1 mean
= 30.50 ± 4.94 µV, n=4; log 0.7 WT hAIPL1 mean = 95.80 ± 6.02 µV, n=5; log 0.7 P351Δ12
hAIPL1 mean = 42.50 ± 7.00 µV, n=4; log 0.9 WT hAIPL1 mean = 110.0 ± 6.00 µV, n=5; log
0.9 P351Δ12 hAIPL1 mean = 47.00 ± 10.31 µV, n=4) (Fig. 3A, C). Scotopic, rod-mediated ERG
responses were also reduced, although less drastically, to approximately 50-70% of WT hAipl1
ERG levels, with greater reduction at lower flash intensities (Fig. 3B, C) (p values as indicated,
ranging from p < 0.05 to p < 0.0005). We therefore examined the intensity-response relationship
from scotopic ERG measurements and found that rods from mutant P351Δ12 hAipl1 mice had a
higher half-saturating light intensity compared to WT hAipl1 (Fig. 3D), indicating reduced
sensitivity.

86

P351Δ12 hAipl1 mice show accelerated decline of photopic responses and gradual decline of
scotopic responses
To evaluate whether the visual defect was progressive or stationary, we measured ERG
responses in animals of increasing age. P351Δ12 hAipl1 mice showed a rapid decline in photopic
cone-mediated ERG responses decreasing to approximately 10% by P60. The 10% of WT hAipl1
photopic response comes from several P351Δ12 hAipl1 mice that showed small phototopic
responses, whereas the other half of the mutant mice had completely abolished photopic ERG
responses. This trend was similar at P90-P120, resulting in approximately 5% of WT hAipl1
photopic response.
Scotopic, rod-mediated ERG responses also decreased albeit at a much slower rate (Fig.
4, dashed line). The largest decline in scotopic response in P351Δ12 hAipl1 mice was observed
between P60 and P90, where 49% of WT hAipl1 response decreased to 37% and remained stable
until P360 (P360 data not shown).

P351Δ12 hAipl1 mice show decreased visual behavior
To determine whether decreased ERG responses affected functional vision in mutant
P351Δ12 hAipl1 mice, we performed behavioral tests based on the ability of the mouse to
reflexively track computer-generated sinusoidal gratings (Douglas et al., 2005). Visual acuity is
evaluated by measuring the threshold (maximal) spatial frequency of the gratings that elicits an
optokinetic response from the mouse. Measurements are conducted under photopic and scotopic
conditions (Kolesnikov et al., 2010). At P30, P351Δ12 hAipl1 mice showed significantly lower
optokinetic responses under photopic conditions (Fig. 5A, photopic left) (p = 0.0184; WT mean
= 0.5339 ± 0.03541 cyc/deg, n=5; P351Δ12 mean = 0.3298 ± 0.0045 cyc/deg, n=2). Under
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scotopic conditions, mutant mice showed a trend toward lower optokinetic responses than
wildtype, however, a significant decrease was observed at only one scotopic background light
intensity (Fig. 5A, scotopic right) (p = 0.036; WT mean = 0.4048 ± 0.02497 cyc/deg, n=5;
P351Δ12 mean = 0.2882 ± 0.022 cyc/deg, n=2).
Functional vision further decreased at P60, where the maximal spatial frequency that
P351Δ12 hAipl1 mice respond to optokinetically was lower than that of WT hAipl1 mice, under
all scotopic background light intensities (Fig. 5B, scotopic right) (p values as indicated, ranging
from p < 0.05 to p < 0.0005). Although significantly decreased, some optokinetic response could
still be elicited under scotopic conditions. This differed from measurements under photopic
conditions, where mutant P351Δ12 hAipl1 mice showed no reliable optokinetic response (Fig.
5B, photopic left) (p = 0.0006; WT mean = 0.4087 ± 0.04430 cyc/deg, n=6; P351Δ12 mean =
0.1052 ± 0.0004861 cyc/deg, n=4). Additionally, we confirmed that photopic conditions used
were specifically measuring cone-mediated visual behavior with cpfl1 mutant mice (generously
provided Dr. Bo Chang, Jackson Labs), which lack photopic ERG responses due to a
spontaneous mutation in cone phosphodiesterase 6 (cPDE6). Adult cpfl1 mice showed no
reliable optokinetic response under photopic conditions (data not shown).

Cone photoreceptor cell death and cone outer segment disorganization in P351Δ12 hAipl1
mice.
Because of the observed defects in photopic vision, we examined cone outer segment
morphology and cone photoreceptor cell death. At P17, early photoreceptor cell death was
observed in retinal sections from P351Δ12 hAipl1 mice through propidium iodide (Fig. 6A,
propidium iodide red), where strong staining indicate dead cells. A majority of dead cells were
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located at the top edge of the outer nuclear layer (ONL) where cone cell nuclei typically reside.
Some propidium iodide positive cells co-localized with red/green opsin (Fig. 6A, green),
whereas non-co-localizing dead cells likely indicates blue cone cell death. Despite the observed
cone cell death at P17, remaining cones showed intact cone outer segments of relatively
comparable length to WT hAipl1 cones, as indicated by R/G opsin staining (Fig. 6A, R/G opsin,
green, and Supplemental Fig. 1). However, by P35, cone arrestin staining (Fig. 6B, cArr red)
showed cone outer segment shortening (white arrows indicate cone outer segments).

P351Δ12 hAipl1 mice show decreased cone phosphodiesterase 6 and rod transducin α
Through immunocytochemistry, we observed that mutant P351Δ12 hAipl1 mice show
decreased expression of cone PDEα’ early on at P15 (Fig. 7A), which was confirmed with semiquantitative immunoblotting (Fig. 7B). This decrease was specific to cone PDEα’, as levels of
cone transducin α, another cone outer segment protein, were similar in mutant P351Δ12
compared to wildtype hAipl1 mice (Fig. 7B). There is a possible decrease in GC-E in cones as
observed through immunocytochemistry at P15 (data not shown) and P35 (Fig. 4B); however,
this was not observed in immunoblots (Fig. 7B) due to the expression of GC-E in both rods and
cones, where 97% of photoreceptors are rods in the mouse retina. Lastly, we observed a slight
decrease in levels of rod transducin α (Fig. 7B), which may account for the decreased rod
sensitivity and defects in rod-mediated vision observed at P15 (Fig. 2B, C, D).

Gene delivery of WT hAipl1 into mutant P351Δ12 hAipl1 mice
To address whether the P351Δ12 hAipl1 mutation acts in a dominant fashion, we
introduced WT hAipl1 into mutant mice through two means. First, we generated double
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transgenic mice by crossing WT hAipl1 with P351Δ12 hAipl1 mice, which were both flag-tagged
at the N-terminus of AIPL1 (Fig. 1B). Double transgenic mice which co-express WT and
P351Δ12 hAIPL1 (blue and red waveforms) continue to show a defect in cone-mediated ERG
responses, as compared to a littermate expressing WT hAIPL1 (black waveforms) (Fig. 8A, B).
Rod-mediated scotopic ERG responses were also decreased in double transgenic mice as
compared to their WT hAipl1 littermate, although ERG responses were slightly greater than
previously observed in single transgenic P351Δ12 hAipl1 mice. However, a direct comparison
was not possible as no single transgenic P351Δ12 hAipl1 mice were found in the litters analyzed.
This may be explained by the observed protein levels where, in our single transgenic mice,
mutant P351Δ12 hAIPL1 was slightly less (< 2-fold) than WT hAIPL1 in each respective
transgenic line, whereas the amount of P351Δ12 hAIPL1 was approximately 5-fold less than the
co-expressed WT hAIPL1 in double transgenic positive mice.
The second method expressed a non-tagged WT hAIPL1 via AAV-mediated gene
delivery into transgenic mutant P351Δ12 hAipl1 mice, using a previously published scAAV8Y733F-RKp-hAipl1 viral vector (Ku et al., 2011). We first administered gene delivery at P15 and
observed rescue of photopic cone-mediated ERG responses (p = 0.0401; treated mean = 30.67 ±
3.844 µV, n=3; untreated mean = 6.33 ± 6.33 µV, n=3), but not scotopic rod-mediated responses.
We then administered gene delivery at P10 to ensure that lack of rod-meditated rescue was not
due to early rod photoreceptor loss. However, P10 gene delivery of WT hAipl1 also did not
improve rod-mediated ERG responses, although cone-mediated rescue was improved by earlier
gene delivery at P10 over P15 (p = 0.0235; P10 treated mean = 62.0 ± 8.386 µV, n=3; P15
treated mean = 30.67 ± 3.844 µV, n=3) (Fig. 9A, B). Rescue effects on cone-mediated ERG
responses following one AAV treatment administered either at P10 or P15 were observed until
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P130, the last tested age. Additionally, photopic ERG responses in rescued eyes did not change
longitudinally between P30, the first ERG testing date, and P130, the last ERG age tested. Conemediated visual behavior as measured through optokinetic responses was greater in treated eyes
as compared to untreated eyes (p = 0.0105; treated eye mean = 0.4278 ± 0.09206 cyc/deg, n=4;
untreated eye mean = 0.09625 ± 0.06172 cyc/deg, n=4) (Fig. 10).
To resolve the difference we see in introduction of WT hAipl1 through AAV-mediated
gene delivery as compared to genetic manipulation, protein expression of WT hAIPL1 was
compared between the two methods. We observed a drastically greater expression of WT
hAIPL1 in AAV-treated eyes as compared to double transgenic mice (Fig. 11). Although the WT
hAIPL1 band could not be fully resolved from the Flag P351Δ12 hAIPL1 band in AAV-treated
eyes, we estimate (non-tagged) WT hAIPL1 to be in at least 25-fold excess of mutant P351Δ12
hAIPL1, whereas Flag WT hAIPL1 in double transgenic mice are about 5-fold excess of Flag
P351Δ12 hAIPL1 (Fig. 11).
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Discussion
Our studies demonstrate that P351Δ12 hAipl1, a rare mutation reported in two probands,
is associated with retinal degeneration of a CORD phenotype. The patients, however, had
discordant diagnoses; one with CORD and the other with juvenile RP, although both were
reported to have likely inherited the mutation in an autosomal dominant manner (Sohocki et al.,
2000b). Our transgenic P351Δ12 hAipl1 mouse model shows an early loss of cone-mediated
vision and subsequent cone photoreceptor degeneration. We attribute cone defects to decreased
cone PDE6α’, which despite lower expression levels, appeared to localize correctly prior to later
cone outer segment disorganization and degeneration. Additionally, we observed decreased
expression of guanylyl cyclase-E in cone photoreceptors through immunohistochemistry;
however, due to the expression of GC-E in both rods and cones and the overwhelming number
of rods in retina compared to cones, we were unable to confirm this in semi-quantitative
immunoblots. Additionally, mutant mice showed early subtle defects in rod-mediated vision,
particularly with decreased sensitivity, which may be associated with the observed decrease in
rod transducin α. Despite this finding however, rod-mediated vision decreased at a very slow
rate, plateauing around P120.
Interestingly, through our double transgenic experiments, we observed that the P351Δ12
hAipl1 mutation acted in a dominant fashion in that cone-mediated vision could not be rescued
with genetic re-introduction of WT hAipl1. Expression levels of WT hAIPL1 and P351Δ12
hAIPL1 in double transgenic positive mice were relatively comparable. This mimicks a
heterozygous state of P351Δ12 hAipl1, similar to what would occur in the reported P351Δ12CORD and RP patients. Therefore, our mouse model which shows a CORD phenotype,
confirms the dysfunction associated with the P351Δ12 hAipl1 mutation even in a heterozygous
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state. The varying phenotypes between patients with this mutation remains unresolved,
however, we speculate that it may be due to differences in ratios of WT to mutant AIPL1
protein in rods and cones.
Despite the autosomal dominant inheritance pattern in patients and the dominant-like
phenotype observed in our double transgenic animals, cone-mediated vision was improved
following AAV-mediated gene replacement of WT hAipl1 in mutant P351Δ12 hAipl1 mice.
This is likely due to the high protein expression of WT hAIPL1 achieved in treated animals.
Treated mutant mice however, did not show any appreciable improvement in scotopic rodmediated vision, despite the overwhelming amount of WT hAIPL1 protein expressed. This may
be due to local retinal damage from AAV injections that negates any improvement that can be
seen overall. Alternatively, it may suggest that the P351Δ12 hAIPL1 acts in a dominant
negative fashion which cannot be overcome with excess WT hAIPL1 in rods, and implicates a
difference in Aipl1 function in rods and cones that may be attributable to the AIPL1 hinge
region.
The function of the AIPL1 hinge region remains in question; however, our model clearly
shows detrimental effects of mutations in this region. It is possible that the dominant negative
effects of the P351Δ12 hAipl1 mutation are exerted through this C-terminal primate-specific
region, as transgenic positive P351Δ12 hAipl1 in a mAipl1 heterozygous background (P351Δ12
hAipl1 (mAipl1+/-)) show no visual dysfunction (Supplementary Fig. 2). However, whether the
dominant negative effects stem from a negative interaction between wildtype and P351Δ12
hAIPL1, or alternatively, mutant P351Δ12 hAIPL1 negatively interacting with other essential
photoreceptor proteins remains to be determined.
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Multiple pre-clinical AAV-mediated rescue studies of defects in aryl hydrocarbon
receptor interacting protein like-1 (Aipl1) have been recently conducted on previously reported
Aipl1 mouse models (Tan et al., 2009; Sun et al., 2010; Ku et al., 2011). Aipl1-null mice which
show the most severe and rapidly progressing degeneration of all retinal dystrophy models,
mimicks truncation mutation W278X, the most prevalent mutation in Aipl1-LCA patients
(Sohocki et al., 2000a; Sohocki et al., 2000b; Dharmaraj et al., 2004; Testa et al., 2011).
Successful rescue of Aipl1-null mice provided proof-of-principle demonstrating that if the most
severe of retinal degenerations is rescued, other Aipl1 defects may potentially be treated (Tan et
al., 2009; Sun et al., 2010; Ku et al., 2011). However, the practical clinical target would likely be
a less severely implicated Aipl1 mutation. Our novel transgenic P351Δ12 hAipl1 mouse offers a
model to study Aipl1-CORD patients, and while these patients are rare, may benefit from gene
replacement therapy.
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Figures
Fig. 1

Fig. 1. The P351∆12 hAipl1 mutation interrupts a putative PxxP motif in the C-terminal
proline-rich hinge region of hAIPL1. (A) The 12 bp deletion (blue arrow, underline, and box)
results in a 4 amino-acid in-frame deletion, eliminating 1 of 5 potential PxxP motifs (black
underline) present in the C-terminal proline-rich, primate-specific region (grey box) of hAipl1.
(B) Transgenic mice were generated expressing either N-terminal Flag-tagged wildtype hAipl1
(control transgenic line) or Flag-tagged P351∆12 hAipl1 (experimental line) under the 2.3 kb
mCrx promoter.
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Fig. 2

Fig. 2. Expression of Flag-P351∆12 hAIPL1 is comparable to Flag-wildtype (WT) hAIPL1.
Immunoblots of P10 retinal lysates from transgenic WT hAipl1 and P351∆12 hAipl1 mice
probed with anti-AIPL1 that recognizes both mouse and human AIPL1 equally (gift from Dr.
Tiansen Li). Equal amounts of protein were loaded for each sample (150 μg). mAIPL1: mouse
AIPL1, hAIPL1: human AIPL1, Tg: transgenic hAIPL1.
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Fig. 3

Fig. 3. Mice with P351∆12 hAipl1 mutation show an early dramatic decrease in photopic
vision and defects in scotopic vision. Families of representative ERG responses from postnatal
day 15 (P15) wildtype hAipl1 and mutant P351∆12 hAipl1 mice, as recorded under (A) photopic
and (B) scotopic conditions at indicated log intensity (cd · s / m2) flashes. (C) Comparison of
mean cone and rod photoreceptor responses (a-wave amplitudes) between WT (white bar; n=5)
and P351∆12 hAipl1 (grey bar; n=4). Average a-wave amplitudes (± SEM) from WT hAipl1
mice were significantly different from P351∆12 hAipl1 mice at all photopic and scotopic flash at
indicated scotopic flash intensities. P values are indicated as follows: *P < 0.05, ** P < 0.005,
*** P < 0.0005. (D) Intensity-response relationship for scotopic a-wave amplitude, where data
was fitted with hyperbolic function (Fulton and Rushton 1978), A = Amax ((In) / ( In + Inh )),
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where Amax is the maximal a-wave amplitude, n is the Hill coefficient, and Ih is the halfsaturating light intensity. This curve fit yielded scotopic a-wave half-saturating light intensities
of 0.03346 ± 0.003360 cd · s / m2 (WT hAipl1, n=5) and 0.05774 ± 0.004798 cd · s / m2
(P351∆12 hAipl1, n=4). Data points are mean ± SEM.
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Fig. 4

Fig. 4. Accelerated loss of photopic ERG responses with slower decline in scotopic ERG
responses in P351∆12 hAipl1 mutant mice. ERG responses over time (from P15 to P120), as
expressed as the ratio of (P351Δ12 hAipl1 / WT hAipl1) a-wave amplitudes, obtained from
measurements taken with 2.5x10-2 cd · s / m2 flashes under scotopic, rod-mediated conditions
(dashed line) and 2.5 cd · s / m2 flashes under photopic, cone-mediated conditions (solid line)
(P15, n=4; P30, n=6; P60, n=5; P90, n=5; P120, n=5).
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Fig. 5

Fig. 5. P351Δ12 hAipl1 mice show impaired visual function. Mean threshold spatial
frequencies (cyc/deg) of WT (n=5) and P351Δ12 hAipl1 (n=2) mice, obtained using OptoMotry,
a virtual optokinetic stimuli apparatus (CerebralMechanics, Inc.) at (A) postnatal day 30 (P30),
and (B) postnatal day 60 (P60). Multiple measurements were obtained across the indicated
background light intensities under scotopic conditions. Bars and data points are mean ± SEM
values. P values are indicated as follows: *P < 0.05, ** P < 0.005, *** P < 0.0005.
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Fig. 6

Fig. 6. Cone degeneration and cone outer segment shortening in mice with P351∆12 hAipl1
mutation. Immunocytochemistry using indicated antibodies on retinal sections from WT hAipl1
and P351∆12 hAipl1 mice. (A) Propidium iodide (red) was used as a marker of cell death,
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showing photoreceptor cell death along cone nuclei stained with red/green (R/G) opsin (green) in
retinal sections from postnatal day 17 (P17) mutant P351∆12 hAipl1 (bottom two rows) but not
WT hAipl1 (top row) mice. (B) Rod and cone outer segments are localized with guanylate
cyclase (GCE, green) with specific localization of cone outer segments (white arrowheads) using
the cone arrestin antibody (cArr, red) in postnatal day 35 (P35) WT hAipl1 (top row) and
P351∆12 hAipl1 mutant mice (bottom two rows) retinal sections. Cell nuclei are stained with
DAPI (4’,6-diamidino-2-phenylindole, blue). COS: cone outer segment, CIS: cone inner
segment, ONL: outer nuclear layer. Scale bar, 20 μm.

103

Fig. 7

Fig. 7. P351∆12 hAipl1 mutant mice show decreased cone phosphodiesterase 6. (A)
Immunostaining of retinal sections from P15 (top two rows) and P35 (bottom two rows) WT
hAipl1 and P351∆12 hAipl1 mice with antibody for cone phosphodiesterase α’ subunit
(cPDE6α’, green), co-stained with cone marker, peanut agglutinin (PNA, red). Cell nuclei are
stained with DAPI (4’,6-diamidino-2-phenylindole, blue). Scale bar, 20 µm. COS, cone outer
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segment; CIS, cone inner segment; ONL, outer nuclear layer. (B) Immunoblots of retinal lysates
from P35 WT hAipl1 and P351∆12 hAipl1 mice probed with the indicated antibodies against
cone photoreceptor proteins, cone PDE α’ and cone transducin α; and rod proteins, rod
transducin α. Guanylyl cyclase (GC-E) is present in both cones and rods.
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Fig. 8

Fig. 8. Double transgenic mice expressing WT and P351Δ12 hAIPL1 show defects in conemediated vision. P351Δ12 hAipl1 mice were crossed with WT hAipl1 mice to generate offspring
which are potentially double transgenic positive. (A) Co-expression of WT and mutant P351Δ12
hAIPL1 was evaluated by extensively running a 9% polyacrylamide SDS-PAGE resolving gel of
16 cm height. Controls (Control: Flag WT and Flag Mut lanes), are run on the same gel to show
the expected size differences. (B) ERG responses from the corresponding individual mice shown
in the immunoblot. Photopic and scotopic responses from a mouse expressing Flag WT hAIPL1
(Flag WT lane in immunoblot; black ERG waveforms), and two independent mice co-expressing
Flag-WT and Flag-P351Δ12 hAIPL1 (2xFlag Tg 1, 2 in immunoblot; blue and red ERG
waveforms).
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Fig. 9

Fig. 9. WT hAipl1 gene replacement into mutant P351Δ12 hAipl1 mice rescued cone- but
not rod-mediated ERG responses. AAV-mediated gene delivery using scAAV8-hRK-hAipl1
viral vector, which introduced non-tagged WT hAipl1 into mutant P351Δ12 hAipl1 mice
administered either at P10 or P15. Treated eyes showed improved (A) cone-mediated ERG
responses, but not (B) rod-mediated ERG responses, when compared directly to its untreated eye.
Measurements shown were obtained at P30 with 2.5 cd · s / m2 flashes with 30 cd/m2 roddesensitizing white background light for photopic ERG responses, and 2.5x10-2 cd · s / m2 flashes
for scotopic ERG responses. Bars and data points are mean ± SEM values. P values are indicated
as follows: *P < 0.05, ** P < 0.005.
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Fig. 10

Fig. 10. Treated P351Δ12 hAipl1 mice showed cone-mediated visual function. Threshold
spatial frequencies (cyc/deg) as measured using OptoMotry, from mutant P351Δ12 hAipl1 mice
that received AAV-mediated gene delivery of WT hAipl1 in one eye (treated) whereas the
opposite eye remained untreated (n=4). Data points are individual threshold spatial frequency
values, with connecting lines indicating the untreated and treated eye from the same mouse. Bars
show mean ± SEM values (cyc/deg) of untreated and treated groups respectively, which were
significantly different (*P < 0.05).
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Fig. 11

Fig. 11. Gene introduction through AAV-mediated gene delivery shows drastically higher
expression of WT hAipl1 than in double transgenic animals. To differentiate flag-tagged WT,
flag-tagged mutant P351Δ12 hAIPL1, and non-tagged WT hAIPL1, we extensively ran a 9%
polyacrylamide SDS-PAGE resolving gel of 16 cm height. Controls are run on the same gel to
show the expected size differences. Flag-tagged WT hAIPL1 (Control: Flag WT lane), flagtagged P351Δ12 hAIPL1 (Control: Flag Mut lane), and non-tagged WT hAIPL1 (Control: No
tag WT lane), show slight band shifts from highest to lowest in immunoblots, respectively. The
control non-tagged WT hAIPL1 lane is from retinal lysate of pNrl-hAipl1 transgenic mice
(Kirschman et al., 2010). Double transgenic animals were generated by crossing Flag-WT hAipl1
mice with Flag-P351Δ12 hAipl1 mice, and retinal lysate from three separate animals are shown
(2xFlag Tg lanes). Flag-P351Δ12 hAipl1 mice were administered AAV-mediated gene delivery
of non-tagged WT hAipl1, using a scAAV8-Y733F-hAipl1 viral vector (Ku et al., 2011), and
retinal lysate from three separate animals are shown (AAV-treated 1, 2, 3 lanes). Retinal lysate
from double transgenic mice were age-matched to AAV-treated mice aged P130, and equal
protein (150 µg) was loaded for all lanes.
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Supplementary Fig. 1

Supplementary Fig. 1. Cone outer segments are of relatively normal length at early ages in
P351Δ12 hAipl1 mice. Immunostaining of retinal sections from P15 WT hAipl1 and P351Δ12
hAipl1 mice with red/green opsin (green) and peanut agglutinin (PNA, red) showing cone outer
segments. Cell nuclei are stained with DAPI (4’,6-diamidino-2-phenylindole, blue). Scale bar, 20
µm. COS, cone outer segment; CIS, cone inner segment; ONL, outer nuclear layer.
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Supplementary Fig. 2

Supplementary Fig. 2. Mice positive for P351Δ12 hAipl1 transgene in a mAipl1+/background do not show visual dysfunction. (A) Photopic, cone-mediated, and (B) scotopic,
rod-mediated ERG responses of mutant P351Δ12 hAipl1 in a mAipl1+/- background (P351Δ12
hAIPL1+ mAIPL1(+/-), middle column) mice are similar to control transgene negative mAipl1+/mice (mAIPL1(+/-), left column), in contrast to the absent photopic response and decreased
scotopic responses from mutant P351Δ12 hAipl1 in a mAipl1-/- background (P351Δ12 hAIPL1+
mAIPL1(-/-), right column) mice, even at older ages tested (P170 shown). Photopic and scotopic
measurements are taken with the indicated log intensity (cd · s / m2) flashes.
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Chapter 4
General Discussion, Conclusion, and Future Work
Study 1: Gene therapy for Aipl1-null mice, a model of severe Leber congenital amaurosis
Recent advancements in AAV viral vectors were developed to treat retinal degeneration
more rapid and severe than that seen with Rpe65-LCA. Developments in self-complementary
AAV and viral capsid mutations demonstrated faster onset and greater transduction efficiency
with fluorescent reporters (Natkunarajah et al., 2008; Zhong et al., 2008b; Petersen-Jones et al.,
2009; Petrs-Silva et al., 2009; Kong et al., 2010; Petrs-Silva et al., 2011). We wanted to examine
whether these improvements translate into functional benefits. In Aipl1-null mice, the most
severe mouse model of retinal degeneration, we evaluated whether the combined selfcomplementary Y733F capsid mutant AAV2/8 (referred to as scAAV) viral vector, would
enhance rescue over single-stranded AAV2/8 (referred to as ssAAV), the most efficient vector
for photoreceptor targeting at that time. We observed clear functional benefits of using scAAV
over ssAAV, particularly when treatment was administered later in disease progression at
postnatal day 10 (P10) when photoreceptor cell death initiates in Aipl1-null mice. Early
intervention at P2 also provided significantly greater ERG levels and morphology in scAAVtreated as compared to ssAAV-treated, although the difference was not to the same degree as that
observed following P10 treatment (Ku et al., 2011).
Since our studies, AAV8-Y733F capsid mutant has been used to successfully rescue
vision in other photoreceptor gene defects, Gucy2e (Boye, S.L. et al., 2011), Pde6brd10 (Pang et
al., 2011), and Pde6anmf363 (Wert et al., 2012). Rescue studies of Gucy2e-null mice
demonstrated functional benefits in cone- and rod-mediated ERG responses with AAV8-Y733F
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over AAV5 viral vector (Boye, S.L. et al., 2011). However, it is unpredictable whether this effect
would still hold up in a comparison with AAV8, since AAV8 was previously shown to be
superior to AAV5 in rapid photoreceptor transduction (Allocca et al., 2007; Lebherz et al., 2008;
Sun et al., 2010). The comparison between ssAAV8 and ssAAV8-Y733F would have been an
important comparison since our studies had used a combined self-complementary Y733F capsid
mutant viral vector, a development that cannot always be taken advantage of with the size
limitation of scAAV. To our knowledge, no other AAV-mediated gene rescue studies for
inherited retinal degeneration have compared the rescue efficacy achieved between viral vectors.
Aipl1-null mice offer a unique model to test the functional utility of future developments
in viral vector efficiency as new advancements emerge, such as viral particles with multiple
surface capsid mutations (Petrs-Silva et al., 2011; Ryals et al., 2011). Lastly, successful rescue of
Aipl1-null mice demonstrated independently by multiple groups (Tan et al., 2009; Sun et al.,
2010; Ku et al., 2011) provides proof-of-concept that even the most severe of retinal
degenerations can be rescued if AAV-mediated gene replacement is provided prior to significant
photoreceptor cell loss.

Study 2: P351Δ12 Aipl1 mutation: a model of cone-rod dystrophy
While Aipl1 is mainly linked to LCA, Aipl1-CORD and -RP patients may more greatly
benefit from AAV-mediated gene replacement since disease progression is prolonged in CORD
and RP as compared to LCA. The P351Δ12 hAipl1 mutation has been associated with CORD and
RP in two probands. We were interested in this mutation not for the sole purpose of pinpointing
one Aipl1 mutation to target with gene therapy, as this would make up a minority of Aipl1
patients even if found in additional cases. Instead, the P351Δ12 mutation brings up additional
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questions, which we sought to answer by creating a transgenic mouse model expressing the
mutant P351Δ12 hAIPL1 protein.
Apart from the W278X truncation mutation shown to translate an unstable protein, it is
unclear why some Aipl1 mutations cause LCA compared to other mutations causing less severe
IRDs. While Aipl1-null mice phenocopies severe LCA and Aipl1-hypomorph mice phenocopies
a very slowly progressing RP, there is no Aipl1 model that phenocopies CORD. With the
association of P351Δ12 hAipl1 to CORD, this transgenic mouse model may offer some insight to
the role of hAipl1 in cones. The P351Δ12 hAipl1 is also associated with autosomal dominant
disease which we thought a priori would preclude it from benefitting from AAV-mediated gene
replacement therapy. However, the autosomal dominant inheritance pattern brought up
interesting possibilities in examining abnormal and normal interacting protein partners of hAipl1,
since it signifies a possible dominant negative effect of the mutation.
We investigated the phenotype of mice expressing mutant P351Δ12 hAIPL1 and
observed visual defects mimicking cone-rod dystrophy (CORD). This is in agreement with a
reported P351Δ12 hAipl1 patient, although a second patient had a discordant diagnosis of
juvenile RP (Sohocki et al., 2000b). In our transgenic P351Δ12 hAipl1-CORD model, we
attribute the observed cone defects to decreased cone phosphodiesterase 6 (cPDE6). In addition
to dramatic cone defects, we observed early defects at postnatal day 15 in rod-mediated ERG
responses and subsequent rod cell loss, which we attribute to decreased rod transducin. A
reduction in rod transducin would produce subsequent defects in signal transduction, which is
reflected in our observations of reduced sensitivity in rod-mediated vision in P351Δ12 hAipl1
mice.

114

P351Δ12 hAipl1 was specifically linked with autosomal dominant retinal degeneration,
which has not been otherwise observed with Aipl1 defects. We confirmed autosomal dominant
disease associated with the P351Δ12 mutation through double transgenic mice co-expressing WT
and mutant P351Δ12 hAIPL1, which continued to show cone and rod visual defects. However,
drastic overexpression of WT hAIPL1 with AAV-mediated gene delivery into P351Δ12 hAipl1
mice rescued cone, although not rod, defects. Further work is needed to examine the mechanism
of dominant dysfunction with P351Δ12 hAIPL1, which may differ in cones and rods as
suggested by these rescue studies.
This also implicates that the normal role of Aipl1 differs in cones and rods, a question
that is currently being investigated in a ‘cone-only’ retina lacking mAipl1 (Nrl-/-/Aipl1-/- double
knockout mice) (Kolandaivelu et al., manuscript in preparation). Nrl (neural retina-specific
leucine zipper) is an important transcription factor specifying rod photoreceptor differentiation,
therefore, all photoreceptors develop into cone-like cells in Nrl-/- mice. In Nrl-/-/Aipl1-/- mice,
the lack of mAipl1 in cones leads to de-stabilized cPDE6 observed in pulse-chase experiments
and a subsequent dramatic decrease in cPDE6 levels (Kolandaivelu et al., manuscript in
preparation). These studies affirm the role of Aipl1 in cPDE6, but does not confirm nor exclude a
dominant negative effect of the P351Δ12 hAIPL1 mutation on cPDE6. However, P351Δ12
hAIPL1 dysfunction in cones could potentially be examined through a comparison of interacting
partners between Flag-WT hAIPL1 and Flag-P351Δ12 hAIPL1 in an Nrl-/-/Aipl1-/- background
in future studies.
In regards to the rod dysfunction observed in P351Δ12 hAipl1 mice, decreased rod
transducin may stem from an active dominant negative effect of mutant P351Δ12 hAIPL1 on this
essential phototransduction protein. An alternative explanation is that mutant P351Δ12 hAIPL1
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shows lower stability or activity than WT hAIPL1, resulting in subpar functioning of AIPL1.
This theoretical possibility would also have to assume functional differences between human and
mouse AIPL1, since mAipl1-hypomorphic mice expressing 20-25% of normal mAIPL1 levels do
not show defects in rod transducin (Liu et al., 2004).
A last question that remains to be examined is the role of the C-terminal primate-specific
region in human AIPL1. In addition to ensuring that mutant P351Δ12 hAIPL1 effects were not
due to mCrx promoter insufficiencies, another reason we generated a control WT hAipl1
transgene line was to examine interacting partners of human AIPL1 using the N-terminal flagepitope tag. Initial attempts at flag co-immunoprecipitation were unsuccessful as background
binding to flag agarose beads was high, however, use of flag magnetic beads may yield cleaner
results. Although we were unable to directly answer this question in our current studies, our
findings clearly indicate that mutations in this region lead to visual dysfunction and
degeneration. Altogether, we conclude that our transgenic P351Δ12 hAipl1 mouse offers a novel
model for Aipl1-CORD, which can be further used to evaluate the mechanism of dominant
dysfunction, and that our WT hAipl1 line can be further used to examine the normal role of
hAipl1 in cones.

Summary:
Our work demonstrates that visual dysfunction associated with Aipl1 defects can be
significantly improved with AAV-mediated gene therapy, in both Aipl1-null mice modeling
Aipl1-LCA and transgenic P351Δ12 hAipl1 mice modeling Aipl1-CORD. Although our work
confirms that dominant disease is likely with a P351Δ12 mutation in a heterozygous state,
overexpression of WT hAIPL1 with AAV-mediated therapy can rescue cone defects, and if
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directly targeted to the macula, AAV treatment would still drastically help maintain visual
function in patients. These studies indicate Aipl1 as a potential candidate for future AAV gene
therapy clinical trials, provided that early intervention is administered to a patient with a slower
progressing disease. Additionally, Aipl1 is small enough to be packaged within a selfcomplementary AAV vector with extremely rapid and efficient transduction, which provides an
advantage of targeting Aipl1 over other genes with a similar predicted rapid progression of
retinal degeneration.
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